{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 144254, "items": [{"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T13:17:12Z", "timestamp": 1574428632475}, "reference-count": 54, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 5, 9]], "date-time": "2010-05-09T00:00:00Z", "timestamp": 1273363200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Struct Mol Biol"], "published-print": {"date-parts": [[2010, 6]]}, "DOI": "10.1038/nsmb.1831", "type": "journal-article", "created": {"date-parts": [[2010, 5, 9]], "date-time": "2010-05-09T18:12:09Z", "timestamp": 1273428729000}, "page": "688-695", "source": "Crossref", "is-referenced-by-count": 497, "title": ["53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers"], "prefix": "10.1038", "volume": "17", "author": [{"given": "Peter", "family": "Bouwman", "sequence": "first", "affiliation": []}, {"given": "Amal", "family": "Aly", "sequence": "additional", "affiliation": []}, {"given": "Jose M", "family": "Escandell", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Pieterse", "sequence": "additional", "affiliation": []}, {"given": "Jirina", "family": "Bartkova", "sequence": "additional", "affiliation": []}, {"given": "Hanneke", "family": "van der Gulden", "sequence": "additional", "affiliation": []}, {"given": "Sanne", "family": "Hiddingh", "sequence": "additional", "affiliation": []}, {"given": "Maria", "family": "Thanasoula", "sequence": "additional", "affiliation": []}, {"given": "Atul", "family": "Kulkarni", "sequence": "additional", "affiliation": []}, {"given": "Qifeng", "family": "Yang", "sequence": "additional", "affiliation": []}, {"given": "Bruce G", "family": "Haffty", "sequence": "additional", "affiliation": []}, {"given": "Johanna", "family": "Tommiska", "sequence": "additional", "affiliation": []}, {"given": "Carl", "family": "Blomqvist", "sequence": "additional", "affiliation": []}, {"given": "Ronny", "family": "Drapkin", "sequence": "additional", "affiliation": []}, {"given": "David J", "family": "Adams", "sequence": "additional", "affiliation": []}, {"given": "Heli", "family": "Nevanlinna", "sequence": "additional", "affiliation": []}, {"given": "Jiri", "family": "Bartek", "sequence": "additional", "affiliation": []}, {"given": "Madalena", "family": "Tarsounas", "sequence": "additional", "affiliation": []}, {"given": "Shridar", "family": "Ganesan", "sequence": "additional", "affiliation": []}, {"given": "Jos", "family": "Jonkers", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 5, 9]]}, "reference": [{"key": "BFnsmb1831_CR1", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1016/S0092-8674(02)00615-3", "volume": "108", "author": "AR Venkitaraman", "year": "2002", "unstructured": "Venkitaraman, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171\u2013182 (2002).", "journal-title": "Cell"}, {"key": "BFnsmb1831_CR2", "doi-asserted-by": "publisher", "first-page": "5864", "DOI": "10.1038/sj.onc.1209874", "volume": "25", "author": "K Gudmundsdottir", "year": "2006", "unstructured": "Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864\u20135874 (2006).", "journal-title": "Oncogene"}, {"key": "BFnsmb1831_CR3", "doi-asserted-by": "publisher", "first-page": "633", "DOI": "10.1042/BST0340633", "volume": "34", "author": "SJ Boulton", "year": "2006", "unstructured": "Boulton, S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34, 633\u2013645 (2006).", "journal-title": "Biochem. Soc. Trans."}, {"key": "BFnsmb1831_CR4", "first-page": "1673", "volume": "10", "author": "N Collins", "year": "1995", "unstructured": "Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12\u201313. Oncogene 10, 1673\u20131675 (1995).", "journal-title": "Oncogene"}, {"key": "BFnsmb1831_CR5", "doi-asserted-by": "publisher", "first-page": "128", "DOI": "10.1038/ng1092-128", "volume": "2", "author": "SA Smith", "year": "1992", "unstructured": "Smith, S.A., Easton, D.F., Evans, D.G. & Ponder, B.A. Allele losses in the region 17q12\u201321 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2, 128\u2013131 (1992).", "journal-title": "Nat. Genet."}, {"key": "BFnsmb1831_CR6", "doi-asserted-by": "publisher", "first-page": "362", "DOI": "10.1016/S0959-8049(97)89007-7", "volume": "33", "author": "OT Johannsson", "year": "1997", "unstructured": "Johannsson, O.T. et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer 33, 362\u2013371 (1997).", "journal-title": "Eur. J. Cancer"}, {"key": "BFnsmb1831_CR7", "doi-asserted-by": "publisher", "first-page": "1482", "DOI": "10.1093/jnci/djg050", "volume": "95", "author": "WD Foulkes", "year": "2003", "unstructured": "Foulkes, W.D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 95, 1482\u20131485 (2003).", "journal-title": "J. Natl. Cancer Inst."}, {"key": "BFnsmb1831_CR8", "doi-asserted-by": "publisher", "first-page": "8418", "DOI": "10.1073/pnas.0932692100", "volume": "100", "author": "T Sorlie", "year": "2003", "unstructured": "Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418\u20138423 (2003).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR9", "doi-asserted-by": "publisher", "first-page": "814", "DOI": "10.1038/nrc1457", "volume": "4", "author": "N Turner", "year": "2004", "unstructured": "Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814\u2013819 (2004).", "journal-title": "Nat. Rev. Cancer"}, {"key": "BFnsmb1831_CR10", "doi-asserted-by": "publisher", "first-page": "5885", "DOI": "10.1038/sj.onc.1209871", "volume": "25", "author": "B Evers", "year": "2006", "unstructured": "Evers, B. & Jonkers, J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25, 5885\u20135897 (2006).", "journal-title": "Oncogene"}, {"key": "BFnsmb1831_CR11", "doi-asserted-by": "publisher", "first-page": "298", "DOI": "10.1038/ng0797-298", "volume": "16", "author": "R Hakem", "year": "1997", "unstructured": "Hakem, R., de la Pompa, J.L., Elia, A., Potter, J. & Mak, T.W. Partial rescue of Brca1 (5\u20136) early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298\u2013302 (1997).", "journal-title": "Nat. Genet."}, {"key": "BFnsmb1831_CR12", "doi-asserted-by": "publisher", "first-page": "534", "DOI": "10.1016/j.molcel.2009.06.037", "volume": "35", "author": "L Cao", "year": "2009", "unstructured": "Cao, L. et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 35, 534\u2013541 (2009).", "journal-title": "Mol. Cell"}, {"key": "BFnsmb1831_CR13", "doi-asserted-by": "publisher", "first-page": "1435", "DOI": "10.1126/science.1076182", "volume": "298", "author": "B Wang", "year": "2002", "unstructured": "Wang, B., Matsuoka, S., Carpenter, P.B. & Elledge, S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 298, 1435\u20131438 (2002).", "journal-title": "Science"}, {"key": "BFnsmb1831_CR14", "doi-asserted-by": "publisher", "first-page": "3310", "DOI": "10.1073/pnas.0511259103", "volume": "103", "author": "JC Morales", "year": "2006", "unstructured": "Morales, J.C. et al. 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc. Natl. Acad. Sci. USA 103, 3310\u20133315 (2006).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR15", "doi-asserted-by": "publisher", "first-page": "10079", "DOI": "10.1128/MCB.25.22.10079-10086.2005", "volume": "25", "author": "IM Ward", "year": "2005", "unstructured": "Ward, I.M. et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol. Cell. Biol. 25, 10079\u201310086 (2005).", "journal-title": "Mol. Cell. Biol."}, {"key": "BFnsmb1831_CR16", "doi-asserted-by": "publisher", "first-page": "266", "DOI": "10.1038/90108", "volume": "28", "author": "X Xu", "year": "2001", "unstructured": "Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28, 266\u2013271 (2001).", "journal-title": "Nat. Genet."}, {"key": "BFnsmb1831_CR17", "doi-asserted-by": "publisher", "first-page": "1009", "DOI": "10.1016/S0092-8674(00)81302-1", "volume": "85", "author": "R Hakem", "year": "1996", "unstructured": "Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009\u20131023 (1996).", "journal-title": "Cell"}, {"key": "BFnsmb1831_CR18", "doi-asserted-by": "publisher", "first-page": "12111", "DOI": "10.1073/pnas.0702969104", "volume": "104", "author": "X Liu", "year": "2007", "unstructured": "Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 104, 12111\u201312116 (2007).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR19", "doi-asserted-by": "publisher", "first-page": "32", "DOI": "10.1152/physiolgenomics.00019.2007", "volume": "31", "author": "D Hameyer", "year": "2007", "unstructured": "Hameyer, D. et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 31, 32\u201341 (2007).", "journal-title": "Physiol. Genomics"}, {"key": "BFnsmb1831_CR20", "doi-asserted-by": "publisher", "first-page": "9290", "DOI": "10.1073/pnas.0801017105", "volume": "105", "author": "W Wang", "year": "2008", "unstructured": "Wang, W. et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 105, 9290\u20139295 (2008).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR21", "doi-asserted-by": "publisher", "first-page": "9377", "DOI": "10.1128/MCB.01229-06", "volume": "26", "author": "SR Bartz", "year": "2006", "unstructured": "Bartz, S.R. et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26, 9377\u20139386 (2006).", "journal-title": "Mol. Cell. Biol."}, {"key": "BFnsmb1831_CR22", "doi-asserted-by": "publisher", "first-page": "316", "DOI": "10.1038/nature03097", "volume": "432", "author": "MB Kastan", "year": "2004", "unstructured": "Kastan, M.B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316\u2013323 (2004).", "journal-title": "Nature"}, {"key": "BFnsmb1831_CR23", "doi-asserted-by": "publisher", "first-page": "1803", "DOI": "10.1038/sj.onc.1204252", "volume": "20", "author": "WR Taylor", "year": "2001", "unstructured": "Taylor, W.R. & Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 20, 1803\u20131815 (2001).", "journal-title": "Oncogene"}, {"key": "BFnsmb1831_CR24", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1016/S1097-2765(01)00295-7", "volume": "8", "author": "DP Silver", "year": "2001", "unstructured": "Silver, D.P. & Livingston, D.M. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol. Cell 8, 233\u2013243 (2001).", "journal-title": "Mol. Cell"}, {"key": "BFnsmb1831_CR25", "doi-asserted-by": "publisher", "first-page": "418", "DOI": "10.1038/ng747", "volume": "29", "author": "J Jonkers", "year": "2001", "unstructured": "Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418\u2013425 (2001).", "journal-title": "Nat. Genet."}, {"key": "BFnsmb1831_CR26", "doi-asserted-by": "publisher", "first-page": "37", "DOI": "10.1038/ncb1337", "volume": "8", "author": "A Jazayeri", "year": "2006", "unstructured": "Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37\u201345 (2006).", "journal-title": "Nat. Cell Biol."}, {"key": "BFnsmb1831_CR27", "doi-asserted-by": "publisher", "first-page": "23899", "DOI": "10.1074/jbc.C000276200", "volume": "275", "author": "A Bhattacharyya", "year": "2000", "unstructured": "Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R. & Bishop, D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899\u201323903 (2000).", "journal-title": "J. Biol. Chem."}, {"key": "BFnsmb1831_CR28", "doi-asserted-by": "publisher", "first-page": "5128", "DOI": "10.1073/pnas.89.11.5128", "volume": "89", "author": "H te Riele", "year": "1992", "unstructured": "te Riele, H., Robanus-Maandag, E. & Berns, A. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc. Natl. Acad. Sci. USA 89, 5128\u20135132 (1992).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR29", "doi-asserted-by": "publisher", "first-page": "649", "DOI": "10.1038/348649a0", "volume": "348", "author": "H te Riele", "year": "1990", "unstructured": "te Riele, H., Robanus-Maandag, E., Clarke, A., Hooper, M. & Berns, A. Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature 348, 649\u2013651 (1990).", "journal-title": "Nature"}, {"key": "BFnsmb1831_CR30", "doi-asserted-by": "publisher", "first-page": "3625", "DOI": "10.1158/0008-5472.CAN-08-3426", "volume": "69", "author": "H Holstege", "year": "2009", "unstructured": "Holstege, H. et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625\u20133633 (2009).", "journal-title": "Cancer Res."}, {"key": "BFnsmb1831_CR31", "doi-asserted-by": "publisher", "first-page": "663", "DOI": "10.1158/0008-5472.CAN-08-1560", "volume": "69", "author": "E Manie", "year": "2009", "unstructured": "Manie, E. et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69, 663\u2013671 (2009).", "journal-title": "Cancer Res."}, {"key": "BFnsmb1831_CR32", "doi-asserted-by": "publisher", "first-page": "1226", "DOI": "10.1101/gad.11.10.1226", "volume": "11", "author": "T Ludwig", "year": "1997", "unstructured": "Ludwig, T., Chapman, D.L., Papaioannou, V.E. & Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226\u20131241 (1997).", "journal-title": "Genes Dev."}, {"key": "BFnsmb1831_CR33", "doi-asserted-by": "publisher", "first-page": "671", "DOI": "10.1016/S0140-6736(05)70933-8", "volume": "365", "author": "Y Wang", "year": "2005", "unstructured": "Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671\u2013679 (2005).", "journal-title": "Lancet"}, {"key": "BFnsmb1831_CR34", "doi-asserted-by": "publisher", "first-page": "10669", "DOI": "10.1158/0008-5472.CAN-07-0539", "volume": "67", "author": "G Alexe", "year": "2007", "unstructured": "Alexe, G. et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 67, 10669\u201310676 (2007).", "journal-title": "Cancer Res."}, {"key": "BFnsmb1831_CR35", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1016/j.ccr.2006.01.013", "volume": "9", "author": "AL Richardson", "year": "2006", "unstructured": "Richardson, A.L. et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121\u2013132 (2006).", "journal-title": "Cancer Cell"}, {"key": "BFnsmb1831_CR36", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1016/S0092-8674(00)80503-6", "volume": "90", "author": "R Scully", "year": "1997", "unstructured": "Scully, R. et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425\u2013435 (1997).", "journal-title": "Cell"}, {"key": "BFnsmb1831_CR37", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1016/j.ccr.2009.12.030", "volume": "17", "author": "J Bartek", "year": "2010", "unstructured": "Bartek, J. & Hodny, Z. SUMO boosts the DNA damage response barrier against cancer. Cancer Cell 17, 9\u201311 (2010).", "journal-title": "Cancer Cell"}, {"key": "BFnsmb1831_CR38", "doi-asserted-by": "publisher", "first-page": "935", "DOI": "10.1038/nature08657", "volume": "462", "author": "Y Galanty", "year": "2009", "unstructured": "Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935\u2013939 (2009).", "journal-title": "Nature"}, {"key": "BFnsmb1831_CR39", "doi-asserted-by": "publisher", "first-page": "886", "DOI": "10.1038/nature08593", "volume": "462", "author": "JR Morris", "year": "2009", "unstructured": "Morris, J.R. et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462, 886\u2013890 (2009).", "journal-title": "Nature"}, {"key": "BFnsmb1831_CR40", "doi-asserted-by": "publisher", "first-page": "1416", "DOI": "10.1093/nar/gkl010", "volume": "34", "author": "CX Deng", "year": "2006", "unstructured": "Deng, C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416\u20131426 (2006).", "journal-title": "Nucleic Acids Res."}, {"key": "BFnsmb1831_CR41", "doi-asserted-by": "publisher", "first-page": "2556", "DOI": "10.1128/MCB.23.7.2556-2563.2003", "volume": "23", "author": "IM Ward", "year": "2003", "unstructured": "Ward, I.M., Minn, K., van Deursen, J. & Chen, J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23, 2556\u20132563 (2003).", "journal-title": "Mol. Cell. Biol."}, {"key": "BFnsmb1831_CR42", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1016/j.cell.2010.03.012", "volume": "141", "author": "SF Bunting", "year": "2010", "unstructured": "Bunting, S.F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243\u2013254 (2010).", "journal-title": "Cell"}, {"key": "BFnsmb1831_CR43", "doi-asserted-by": "publisher", "first-page": "547", "DOI": "10.1016/j.molcel.2009.01.024", "volume": "33", "author": "B Shiotani", "year": "2009", "unstructured": "Shiotani, B. & Zou, L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol. Cell 33, 547\u2013558 (2009).", "journal-title": "Mol. Cell"}, {"key": "BFnsmb1831_CR44", "doi-asserted-by": "publisher", "first-page": "1145", "DOI": "10.1200/JCO.2009.22.4725", "volume": "28", "author": "DP Silver", "year": "2010", "unstructured": "Silver, D.P. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145\u20131153 (2010).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnsmb1831_CR45", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1056/NEJMoa0900212", "volume": "361", "author": "PC Fong", "year": "2009", "unstructured": "Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnsmb1831_CR46", "doi-asserted-by": "publisher", "first-page": "17079", "DOI": "10.1073/pnas.0806092105", "volume": "105", "author": "S Rottenberg", "year": "2008", "unstructured": "Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105, 17079\u201317084 (2008).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR47", "doi-asserted-by": "publisher", "first-page": "12117", "DOI": "10.1073/pnas.0702955104", "volume": "104", "author": "S Rottenberg", "year": "2007", "unstructured": "Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 104, 12117\u201312122 (2007).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "BFnsmb1831_CR48", "doi-asserted-by": "publisher", "first-page": "2581", "DOI": "10.1158/0008-5472.CAN-08-0088", "volume": "68", "author": "EM Swisher", "year": "2008", "unstructured": "Swisher, E.M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581\u20132586 (2008).", "journal-title": "Cancer Res."}, {"key": "BFnsmb1831_CR49", "doi-asserted-by": "publisher", "first-page": "3243", "DOI": "10.1158/0008-5472.CAN-07-5480", "volume": "68", "author": "N Shafee", "year": "2008", "unstructured": "Shafee, N. et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243\u20133250 (2008).", "journal-title": "Cancer Res."}, {"key": "BFnsmb1831_CR50", "doi-asserted-by": "publisher", "first-page": "291", "DOI": "10.1038/81583", "volume": "26", "author": "JJ Jacobs", "year": "2000", "unstructured": "Jacobs, J.J. et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26, 291\u2013299 (2000).", "journal-title": "Nat. Genet."}, {"key": "BFnsmb1831_CR51", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1016/S0092-8674(04)00337-X", "volume": "117", "author": "M Tarsounas", "year": "2004", "unstructured": "Tarsounas, M. et al. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 117, 337\u2013347 (2004).", "journal-title": "Cell"}, {"key": "BFnsmb1831_CR52", "doi-asserted-by": "publisher", "first-page": "11731", "DOI": "10.1074/jbc.C300023200", "volume": "278", "author": "AM Dirac", "year": "2003", "unstructured": "Dirac, A.M. & Bernards, R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278, 11731\u201311734 (2003).", "journal-title": "J. Biol. Chem."}, {"key": "BFnsmb1831_CR53", "doi-asserted-by": "publisher", "first-page": "247", "DOI": "10.1016/S0076-6879(01)33060-4", "volume": "333", "author": "I Palmero", "year": "2001", "unstructured": "Palmero, I. & Serrano, M. Induction of senescence by oncogenic Ras. Methods Enzymol. 333, 247\u2013256 (2001).", "journal-title": "Methods Enzymol."}, {"key": "BFnsmb1831_CR54", "doi-asserted-by": "publisher", "first-page": "1115", "DOI": "10.1038/sj.onc.1206263", "volume": "22", "author": "M Tarsounas", "year": "2003", "unstructured": "Tarsounas, M., Davies, D. & West, S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 22, 1115\u20131123 (2003).", "journal-title": "Oncogene"}], "container-title": ["Nature Structural & Molecular Biology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nsmb.1831.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nsmb.1831", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nsmb.1831.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 3]], "date-time": "2019-05-03T04:24:06Z", "timestamp": 1556857446000}, "score": 60.854446, "issued": {"date-parts": [[2010, 5, 9]]}, "references-count": 54, "journal-issue": {"published-print": {"date-parts": [[2010, 6]]}, "issue": "6"}, "alternative-id": ["BFnsmb1831"], "URL": "http://dx.doi.org/10.1038/nsmb.1831", "relation": {"cites": []}, "ISSN": ["1545-9993", "1545-9985"], "issn-type": [{"value": "1545-9993", "type": "print"}, {"value": "1545-9985", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:17Z", "timestamp": 1574539157969}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2012, 12, 15]]}, "DOI": "10.1158/0008-5472.sabcs12-p2-10-14", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:35:55Z", "timestamp": 1408055755000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P2-10-14: Triple Negative Breast Cancer: prognosis of triple-negative breast cancers and non-triple-negative breast cancers in a large registry of certified breast units"], "prefix": "10.1158", "author": [{"given": "P", "family": "Kern", "sequence": "first", "affiliation": []}, {"given": "M", "family": "Rezai", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 14]]}, "event": {"name": "Abstracts: Thirty-Fifth Annual CTRC\u2010AACR San Antonio Breast Cancer Symposium\u2010\u2010 Dec 4\u20108, 2012; San Antonio, TX"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS12-P2-10-14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T18:48:34Z", "timestamp": 1558205314000}, "score": 43.178814, "issued": {"date-parts": [[2012, 12, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS12-P2-10-14"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs12-p2-10-14"}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T20:11:14Z", "timestamp": 1574799074695}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2016, 2, 15]]}, "DOI": "10.1158/1538-7445.sabcs15-ot2-05-04", "type": "proceedings-article", "created": {"date-parts": [[2016, 5, 20]], "date-time": "2016-05-20T08:47:55Z", "timestamp": 1463734075000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Abstract OT2-05-04: The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple-negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes"], "prefix": "10.1158", "author": [{"given": "A", "family": "Afghahi", "sequence": "first", "affiliation": []}, {"given": "P-J", "family": "Chang", "sequence": "additional", "affiliation": []}, {"given": "JM", "family": "Ford", "sequence": "additional", "affiliation": []}, {"given": "ML", "family": "Telli", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2016, 2, 18]]}, "event": {"name": "Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX"}, "container-title": ["Ongoing Clinical Trials"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.SABCS15-OT2-05-04", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T16:52:22Z", "timestamp": 1558198342000}, "score": 34.647236, "issued": {"date-parts": [[2016, 2, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.SABCS15-OT2-05-04"], "URL": "http://dx.doi.org/10.1158/1538-7445.sabcs15-ot2-05-04"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:10:59Z", "timestamp": 1574485859816}, "reference-count": 33, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1", "start": {"date-parts": [[2012, 7, 2]], "date-time": "2012-07-02T00:00:00Z", "timestamp": 1341187200000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions", "start": {"date-parts": [[2012, 7, 2]], "date-time": "2012-07-02T00:00:00Z", "timestamp": 1341187200000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 10]]}, "DOI": "10.1111/j.1365-2559.2012.04253.x", "type": "journal-article", "created": {"date-parts": [[2012, 7, 2]], "date-time": "2012-07-02T15:37:04Z", "timestamp": 1341243424000}, "page": "660-666", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Cytokeratin 7: a re-evaluation of the \u2018tried and true\u2019 in triple-negative breast cancers"], "prefix": "10.1111", "volume": "61", "author": [{"given": "Simone M", "family": "Davion", "sequence": "first", "affiliation": []}, {"given": "Kalliopi P", "family": "Siziopikou", "sequence": "additional", "affiliation": []}, {"given": "Megan E", "family": "Sullivan", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 7, 2]]}, "reference": [{"key": "10.1111/j.1365-2559.2012.04253.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1038/modpathol.2010.200", "article-title": "Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists", "volume": "24", "author": "Badve", "year": "2011", "journal-title": "Mod. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "10869", "DOI": "10.1073/pnas.191367098", "article-title": "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", "volume": "98", "author": "Sorlie", "year": "2001", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1007/s10549-008-0086-2", "article-title": "Pattern of metastatic spread in triple-negative breast cancer", "volume": "115", "author": "Dent", "year": "2009", "journal-title": "Breast Cancer Res. Treat."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "276", "DOI": "10.1016/S0046-8177(88)80520-3", "article-title": "Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins", "volume": "19", "author": "Jarasch", "year": "1988", "journal-title": "Hum. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB5|cit5", "first-page": "205", "article-title": "Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors", "volume": "31", "author": "Moll", "year": "1998", "journal-title": "Subcell. Biochem."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB6|cit6", "first-page": "117", "article-title": "Molecular diversity of cytokeratins: significance for cell and tumor differentiation", "volume": "41", "author": "Moll", "year": "1991", "journal-title": "Acta Histochem. Suppl."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB7|cit7", "first-page": "243", "article-title": "Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations", "volume": "52", "author": "Cooper", "year": "1985", "journal-title": "Lab. Invest."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "747", "DOI": "10.1038/35021093", "article-title": "Molecular portraits of human breast tumours", "volume": "406", "author": "Perou", "year": "2000", "journal-title": "Nature"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "119", "DOI": "10.1007/s004280050226", "article-title": "Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas", "volume": "433", "author": "Malzahn", "year": "1998", "journal-title": "Virchows Arch."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB10|cit10", "first-page": "641", "article-title": "Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas", "volume": "136", "author": "Ramaekers", "year": "1990", "journal-title": "Am. J. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1002/(SICI)1097-0142(19990101)85:1<171::AID-CNCR24>3.0.CO;2-V", "article-title": "Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors", "volume": "85", "author": "Tot", "year": "1999", "journal-title": "Cancer"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "758", "DOI": "10.1016/S0959-8049(02)00008-4", "article-title": "Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma", "volume": "38", "author": "Tot", "year": "2002", "journal-title": "Eur. J. Cancer"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "2727", "DOI": "10.1002/1097-0142(20011115)92:10<2727::AID-CNCR1627>3.0.CO;2-B", "article-title": "The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas", "volume": "92", "author": "Tot", "year": "2001", "journal-title": "Cancer"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "962", "DOI": "10.1038/modpathol.3880175", "article-title": "Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases", "volume": "13", "author": "Chu", "year": "2000", "journal-title": "Mod. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB15|cit15", "first-page": "99", "article-title": "Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas", "volume": "3", "author": "Wang", "year": "1995", "journal-title": "Appl. Immunohistochem. Mol. Morphol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.1136/jcp.52.4.283", "article-title": "Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach", "volume": "52", "author": "Lagendijk", "year": "1999", "journal-title": "J. Clin. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB17|cit17", "first-page": "239", "article-title": "Breast gross cystic disease fluid analysis I. Isolation and radioimmunoassay for a major component protein", "volume": "62", "author": "Haagensen", "year": "1979", "journal-title": "J. Natl Cancer Inst."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "1002", "DOI": "10.1038/sj.bjc.6690799", "article-title": "The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis", "volume": "81", "author": "Clark", "year": "1999", "journal-title": "Br. J. Cancer"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.1007/s00292-001-0496-y", "article-title": "Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor", "volume": "23", "author": "Kaufmann", "year": "2002", "journal-title": "Pathologe"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1309/TDP92PQLDE2HLEET", "article-title": "Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity", "volume": "127", "author": "Bhargava", "year": "2007", "journal-title": "Am. J. Clin. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "587", "DOI": "10.1309/AJCPMFR6OA8ICHNH", "article-title": "Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin", "volume": "135", "author": "Lewis", "year": "2011", "journal-title": "Am. J. Clin. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB22|cit22", "first-page": "860", "article-title": "Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer", "volume": "56", "author": "Watson", "year": "1996", "journal-title": "Cancer Res."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1111/j.1749-6632.2000.tb05521.x", "article-title": "Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer", "volume": "923", "author": "Fleming", "year": "2000", "journal-title": "Ann. N Y Acad. Sci."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "654", "DOI": "10.1038/modpathol.2010.38", "article-title": "A study of immunohistochemical differential expression in pulmonary and mammary carcinomas", "volume": "23", "author": "Yang", "year": "2010", "journal-title": "Mod. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "5367", "DOI": "10.1158/1078-0432.CCR-04-0220", "article-title": "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma", "volume": "10", "author": "Nielsen", "year": "2004", "journal-title": "Clin. Cancer Res."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "264", "DOI": "10.1038/modpathol.3800528", "article-title": "Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma", "volume": "19", "author": "Livasy", "year": "2006", "journal-title": "Mod. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB27|cit27", "first-page": "427", "article-title": "Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies", "volume": "140", "author": "Moll", "year": "1992", "journal-title": "Am. J. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "208", "DOI": "10.1038/modpathol.3800731", "article-title": "Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers", "volume": "20", "author": "Sasaki", "year": "2007", "journal-title": "Mod. Pathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB29|cit29", "first-page": "1221", "article-title": "Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer", "volume": "22", "author": "Fritzsche", "year": "2007", "journal-title": "Histol. Histopathol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "691", "DOI": "10.1200/JCO.2004.01.072", "article-title": "Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time", "volume": "22", "author": "Span", "year": "2004", "journal-title": "J. Clin. Oncol."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1385/ENDO:21:3:245", "article-title": "Relationship between mammaglobin expression and estrogen receptor status in breast tumors", "volume": "21", "author": "Guan", "year": "2003", "journal-title": "Endocrine"}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "R65", "DOI": "10.1186/bcr587", "article-title": "Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype", "volume": "5", "author": "Nunez-Villar", "year": "2003", "journal-title": "Breast Cancer Res."}, {"key": "10.1111/j.1365-2559.2012.04253.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1007/BF00197548", "article-title": "PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast", "volume": "425", "author": "Pagani", "year": "1994", "journal-title": "Virchows Arch."}], "container-title": ["Histopathology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2559.2012.04253.x", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2559.2012.04253.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2012.04253.x/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T20:50:21Z", "timestamp": 1497991821000}, "score": 34.445328, "subtitle": ["CK7 in triple-negative breast cancer"], "issued": {"date-parts": [[2012, 7, 2]]}, "references-count": 33, "journal-issue": {"published-print": {"date-parts": [[2012, 10]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.1365-2559.2012.04253.x", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0309-0167"], "issn-type": [{"value": "0309-0167", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T00:37:32Z", "timestamp": 1574728652086}, "reference-count": 58, "publisher": "Informa UK Limited", "issue": "4", "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["JAK-STAT"], "published-print": {"date-parts": [[2014, 10, 2]]}, "DOI": "10.1080/21623996.2015.1009276", "type": "journal-article", "created": {"date-parts": [[2015, 9, 18]], "date-time": "2015-09-18T06:21:19Z", "timestamp": 1442557279000}, "page": "e1009276", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1\u03b1-mediated angiogenesis"], "prefix": "10.1080", "volume": "3", "author": [{"given": "Gangarao", "family": "Davuluri", "sequence": "first", "affiliation": []}, {"given": "William P", "family": "Schiemann", "sequence": "additional", "affiliation": []}, {"given": "Edward F", "family": "Plow", "sequence": "additional", "affiliation": []}, {"given": "Khalid", "family": "Sossey-Alaoui", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2015, 2, 3]]}, "reference": [{"key": "cit0001", "DOI": "10.3322/caac.20138", "doi-asserted-by": "publisher"}, {"key": "cit0002", "DOI": "10.1016/j.cell.2006.11.001", "doi-asserted-by": "publisher"}, {"key": "cit0003", "DOI": "10.1038/sj.cr.7310118", "doi-asserted-by": "publisher"}, {"key": "cit0004", "DOI": "10.3322/caac.20073", "doi-asserted-by": "publisher"}, {"key": "cit0005", "DOI": "10.1038/35021093", "doi-asserted-by": "publisher"}, {"key": "cit0006", "DOI": "10.1073/pnas.191367098", "doi-asserted-by": "publisher"}, {"key": "cit0007", "DOI": "10.1073/pnas.0932692100", "doi-asserted-by": "publisher"}, {"key": "cit0008", "DOI": "10.1172/JCI45014", "doi-asserted-by": "publisher"}, {"key": "cit0009", "author": "Masuda H", "year": "2013", "journal-title": "Clin Cancer Res"}, {"key": "cit0010", "DOI": "10.3816/CBC.2009.s.008", "doi-asserted-by": "publisher"}, {"key": "cit0011", "DOI": "10.1038/nrclinonc.2010.154", "doi-asserted-by": "publisher"}, {"key": "cit0012", "DOI": "10.2217/14796694.3.1.55", "doi-asserted-by": "publisher"}, {"key": "cit0013", "DOI": "10.1056/NEJMra1001389", "doi-asserted-by": "publisher"}, {"key": "cit0014", "DOI": "10.1158/1078-0432.CCR-08-1208", "doi-asserted-by": "publisher"}, {"key": "cit0015", "DOI": "10.1158/1078-0432.CCR-11-2701", "doi-asserted-by": "publisher"}, {"key": "cit0016", "DOI": "10.2165/11594480-000000000-00000", "doi-asserted-by": "publisher"}, {"key": "cit0017", "DOI": "10.1093/annonc/mds188", "doi-asserted-by": "publisher"}, {"key": "cit0018", "DOI": "10.1155/2012/703858", "doi-asserted-by": "publisher"}, {"key": "cit0019", "DOI": "10.1093/jnci/djr386", "doi-asserted-by": "publisher"}, {"key": "cit0020", "DOI": "10.1007/s10911-012-9266-0", "doi-asserted-by": "publisher"}, {"key": "cit0021", "DOI": "10.1016/j.maturitas.2012.08.006", "doi-asserted-by": "publisher"}, {"key": "cit0022", "DOI": "10.1155/2013/137414", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "cit0023", "first-page": "5", "volume": "22", "author": "Adam MA", "year": "2013", "journal-title": "Adv Clin Exp Med"}, {"key": "cit0024", "author": "Droog M", "year": "2013", "journal-title": "Eur J Pharmacol"}, {"key": "cit0025", "DOI": "10.1586/era.12.138", "doi-asserted-by": "publisher"}, {"key": "cit0026", "DOI": "10.1371/journal.pone.0042895", "doi-asserted-by": "publisher"}, {"key": "cit0027", "DOI": "10.1038/sj.onc.1205734", "doi-asserted-by": "publisher"}, {"key": "cit0028", "DOI": "10.1007/s00335-002-2247-7", "doi-asserted-by": "publisher"}, {"key": "cit0029", "DOI": "10.1074/jbc.M500503200", "doi-asserted-by": "publisher"}, {"key": "cit0030", "DOI": "10.1016/j.yexcr.2005.04.011", "doi-asserted-by": "publisher"}, {"key": "cit0031", "DOI": "10.1074/jbc.M701484200", "doi-asserted-by": "publisher"}, {"key": "cit0032", "DOI": "10.2353/ajpath.2007.060975", "doi-asserted-by": "publisher"}, {"key": "cit0033", "DOI": "10.1074/jbc.M109.034553", "doi-asserted-by": "publisher"}, {"key": "cit0034", "DOI": "10.1002/ijc.25793", "doi-asserted-by": "publisher"}, {"key": "cit0035", "DOI": "10.1371/journal.pone.0110627", "doi-asserted-by": "publisher"}, {"key": "cit0036", "DOI": "10.1158/1541-7786.MCR-11-0311", "doi-asserted-by": "publisher"}, {"key": "cit0037", "DOI": "10.1186/1476-4598-11-5", "doi-asserted-by": "publisher"}, {"key": "cit0038", "author": "Sossey-Alaoui K", "year": "2012", "journal-title": "Semin Cell Dev Biol"}, {"key": "cit0039", "author": "Hannesdottir L", "year": "2013", "journal-title": "Eur J Immunol"}, {"key": "cit0040", "author": "Rovida A", "year": "2013", "journal-title": "MolCancer Ther"}, {"key": "cit0041", "DOI": "10.1007/s10928-013-9317-1", "doi-asserted-by": "publisher"}, {"key": "cit0042", "DOI": "10.1158/0008-5472.CAN-13-0062", "doi-asserted-by": "publisher"}, {"key": "cit0043", "DOI": "10.1042/BST20140234", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "cit0044", "first-page": "161", "volume": "1846", "author": "Gacche RN", "year": "2014", "journal-title": "Biochim Biophys Acta"}, {"key": "cit0045", "DOI": "10.1158/0008-5472.CAN-12-1345", "doi-asserted-by": "publisher"}, {"key": "cit0046", "DOI": "10.1002/ijc.27631", "doi-asserted-by": "publisher"}, {"key": "cit0047", "DOI": "10.1038/sj.bjc.6605850", "doi-asserted-by": "publisher"}, {"key": "cit0048", "DOI": "10.1002/ijc.25964", "doi-asserted-by": "publisher"}, {"key": "cit0049", "DOI": "10.1074/jbc.M111.335000", "doi-asserted-by": "publisher"}, {"key": "cit0050", "author": "Teng Y", "year": "2013", "journal-title": "Carcinogenesis"}, {"key": "cit0051", "author": "Teng Y", "year": "2013", "journal-title": "Oncogene"}, {"key": "cit0052", "DOI": "10.1007/s10549-013-2753-1", "doi-asserted-by": "publisher"}, {"key": "cit0053", "DOI": "10.1002/ijc.22291", "doi-asserted-by": "publisher"}, {"key": "cit0054", "DOI": "10.1038/sj.bjc.6602447", "doi-asserted-by": "publisher"}, {"key": "cit0055", "DOI": "10.1016/j.bbrc.2012.10.037", "doi-asserted-by": "publisher"}, {"key": "cit0056", "DOI": "10.1006/meth.2001.1262", "doi-asserted-by": "publisher"}, {"key": "cit0057", "DOI": "10.1038/nprot.2008.73", "doi-asserted-by": "publisher"}, {"key": "cit0058", "DOI": "10.1074/jbc.M109.085746", "doi-asserted-by": "publisher"}], "container-title": ["JAK-STAT"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 14]], "date-time": "2016-12-14T17:11:07Z", "timestamp": 1481735467000}, "score": 31.93708, "issued": {"date-parts": [[2014, 10, 2]]}, "references-count": 58, "journal-issue": {"published-online": {"date-parts": [[2015, 2, 3]]}, "published-print": {"date-parts": [[2014, 10, 2]]}, "issue": "4"}, "alternative-id": ["10.1080/21623996.2015.1009276"], "URL": "http://dx.doi.org/10.1080/21623996.2015.1009276", "relation": {"cites": []}, "ISSN": ["2162-3996"], "issn-type": [{"value": "2162-3996", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=kjks20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=kjks20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T13:33:17Z", "timestamp": 1574688797459}, "reference-count": 39, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 8, 1]], "date-time": "2015-08-01T00:00:00Z", "timestamp": 1438387200000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/501100006020", "name": "Center for Translational Molecular Medicine", "doi-asserted-by": "crossref", "award": ["03O-104"]}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "thebreastonline.com", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["The Breast"], "published-print": {"date-parts": [[2015, 8]]}, "DOI": "10.1016/j.breast.2015.03.002", "type": "journal-article", "created": {"date-parts": [[2015, 4, 28]], "date-time": "2015-04-28T04:46:54Z", "timestamp": 1430196414000}, "page": "397-405", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy"], "prefix": "10.1016", "volume": "24", "author": [{"given": "Anna", "family": "Miquel-Cases", "sequence": "first", "affiliation": []}, {"given": "Lotte M.G.", "family": "Steuten", "sequence": "additional", "affiliation": []}, {"given": "Valesca P.", "family": "Ret\u00e8l", "sequence": "additional", "affiliation": []}, {"given": "Wim H.", "family": "van Harten", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["The Breast"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0960977615000703?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0960977615000703?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 10, 24]], "date-time": "2019-10-24T15:36:15Z", "timestamp": 1571931375000}, "score": 31.367403, "issued": {"date-parts": [[2015, 8]]}, "references-count": 39, "journal-issue": {"published-print": {"date-parts": [[2015, 8]]}, "issue": "4"}, "alternative-id": ["S0960977615000703"], "URL": "http://dx.doi.org/10.1016/j.breast.2015.03.002", "ISSN": ["0960-9776"], "issn-type": [{"value": "0960-9776", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy", "name": "articletitle", "label": "Article Title"}, {"value": "The Breast", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.breast.2015.03.002", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T03:20:45Z", "timestamp": 1574479245870}, "reference-count": 48, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 11, 16]], "date-time": "2010-11-16T00:00:00Z", "timestamp": 1289865600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2010, 12]]}, "DOI": "10.1186/bcr2776", "type": "journal-article", "created": {"date-parts": [[2010, 11, 16]], "date-time": "2010-11-16T19:14:34Z", "timestamp": 1289934874000}, "source": "Crossref", "is-referenced-by-count": 21, "title": ["Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers"], "prefix": "10.1186", "volume": "12", "author": [{"given": "Nadine", "family": "Tung", "sequence": "first", "affiliation": []}, {"given": "Alexander", "family": "Miron", "sequence": "additional", "affiliation": []}, {"given": "Stuart J", "family": "Schnitt", "sequence": "additional", "affiliation": []}, {"given": "Shiva", "family": "Gautam", "sequence": "additional", "affiliation": []}, {"given": "Katharina", "family": "Fetten", "sequence": "additional", "affiliation": []}, {"given": "Jennifer", "family": "Kaplan", "sequence": "additional", "affiliation": []}, {"given": "Yosuf", "family": "Yassin", "sequence": "additional", "affiliation": []}, {"given": "Ayodele", "family": "Buraimoh", "sequence": "additional", "affiliation": []}, {"given": "Ji-Young", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Attila M", "family": "Sz\u00e1sz", "sequence": "additional", "affiliation": []}, {"given": "Ruiyang", "family": "Tian", "sequence": "additional", "affiliation": []}, {"given": "Zhigang C", "family": "Wang", "sequence": "additional", "affiliation": []}, {"given": "Laura C", "family": "Collins", "sequence": "additional", "affiliation": []}, {"given": "Jane", "family": "Brock", "sequence": "additional", "affiliation": []}, {"given": "Karen", "family": "Krag", "sequence": "additional", "affiliation": []}, {"given": "Robert D", "family": "Legare", "sequence": "additional", "affiliation": []}, {"given": "Dennis", "family": "Sgroi", "sequence": "additional", "affiliation": []}, {"given": "Paula D", "family": "Ryan", "sequence": "additional", "affiliation": []}, {"given": "Daniel P", "family": "Silver", "sequence": "additional", "affiliation": []}, {"given": "Judy E", "family": "Garber", "sequence": "additional", "affiliation": []}, {"given": "Andrea L", "family": "Richardson", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 11, 16]]}, "reference": [{"key": "2755_CR1", "first-page": "471", "volume": "56", "author": "F Eisinger", "year": "1996", "unstructured": "Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996, 56: 471-474.", "journal-title": "Cancer Res"}, {"key": "2755_CR2", "doi-asserted-by": "publisher", "first-page": "435", "DOI": "10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y", "volume": "80", "author": "SE Karp", "year": "1997", "unstructured": "Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997, 80: 435-441. 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y.", "journal-title": "Cancer"}, {"key": "2755_CR3", "doi-asserted-by": "crossref", "first-page": "1642", "DOI": "10.1200/JCO.1998.16.5.1642", "volume": "16", "author": "M Robson", "year": "1998", "unstructured": "Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol. 1998, 16: 1642-1649.", "journal-title": "J Clin Oncol"}, {"key": "2755_CR4", "doi-asserted-by": "publisher", "first-page": "316", "DOI": "10.1016/S0140-6736(97)07065-7", "volume": "351", "author": "LC Verhoog", "year": "1998", "unstructured": "Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998, 351: 316-321. 10.1016/S0140-6736(97)07065-7.", "journal-title": "Lancet"}, {"key": "2755_CR5", "doi-asserted-by": "publisher", "first-page": "2068", "DOI": "10.1002/cncr.10949", "volume": "95", "author": "LA Quenneville", "year": "2002", "unstructured": "Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP: HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer. 2002, 95: 2068-2075. 10.1002/cncr.10949.", "journal-title": "Cancer"}, {"key": "2755_CR6", "doi-asserted-by": "publisher", "first-page": "2310", "DOI": "10.1200/JCO.2002.09.023", "volume": "20", "author": "SR Lakhani", "year": "2002", "unstructured": "Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.", "journal-title": "J Clin Oncol"}, {"key": "2755_CR7", "doi-asserted-by": "publisher", "first-page": "1482", "DOI": "10.1093/jnci/djg050", "volume": "95", "author": "WD Foulkes", "year": "2003", "unstructured": "Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003, 95: 1482-1485.", "journal-title": "J Natl Cancer Inst"}, {"key": "2755_CR8", "doi-asserted-by": "publisher", "first-page": "4282", "DOI": "10.1200/JCO.2008.16.6231", "volume": "26", "author": "DP Atchley", "year": "2008", "unstructured": "Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008, 26: 4282-4288. 10.1200/JCO.2008.16.6231.", "journal-title": "J Clin Oncol"}, {"key": "2755_CR9", "doi-asserted-by": "publisher", "first-page": "2335", "DOI": "10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N", "volume": "83", "author": "JE Armes", "year": "1998", "unstructured": "Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998, 83: 2335-2345. 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N.", "journal-title": "Cancer"}, {"key": "2755_CR10", "doi-asserted-by": "publisher", "first-page": "1138", "DOI": "10.1093/jnci/90.15.1138", "volume": "90", "author": "SR Lakhani", "year": "1998", "unstructured": "Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.", "journal-title": "J Natl Cancer Inst"}, {"key": "2755_CR11", "doi-asserted-by": "publisher", "first-page": "1321", "DOI": "10.1038/modpathol.3800456", "volume": "18", "author": "M Laakso", "year": "2005", "unstructured": "Laakso M, Loman N, Borg A, Isola J: Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005, 18: 1321-1328. 10.1038/modpathol.3800456.", "journal-title": "Mod Pathol"}, {"key": "2755_CR12", "doi-asserted-by": "publisher", "first-page": "5175", "DOI": "10.1158/1078-0432.CCR-04-2424", "volume": "11", "author": "SR Lakhani", "year": "2005", "unstructured": "Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005, 11: 5175-5180. 10.1158/1078-0432.CCR-04-2424.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR13", "doi-asserted-by": "publisher", "first-page": "4003", "DOI": "10.1158/1078-0432.CCR-04-2064", "volume": "11", "author": "JB Arnes", "year": "2005", "unstructured": "Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005, 11: 4003-4011. 10.1158/1078-0432.CCR-04-2064.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR14", "doi-asserted-by": "publisher", "first-page": "2029", "DOI": "10.1158/1078-0432.CCR-03-1061", "volume": "10", "author": "WD Foulkes", "year": "2004", "unstructured": "Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, Narod SA: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004, 10: 2029-2034. 10.1158/1078-0432.CCR-03-1061.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR15", "doi-asserted-by": "publisher", "first-page": "2538", "DOI": "10.1158/0008-5472.CAN-09-2089", "volume": "70", "author": "MT Harte", "year": "2010", "unstructured": "Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB, Harkin DP: BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 2010, 70: 2538-2547. 10.1158/0008-5472.CAN-09-2089.", "journal-title": "Cancer Res"}, {"key": "2755_CR16", "doi-asserted-by": "publisher", "first-page": "1683", "DOI": "10.1093/jnci/djm207", "volume": "99", "author": "AM Hosey", "year": "2007", "unstructured": "Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007, 99: 1683-1694. 10.1093/jnci/djm207.", "journal-title": "J Natl Cancer Inst"}, {"key": "2755_CR17", "doi-asserted-by": "publisher", "first-page": "1514", "DOI": "10.1158/1078-0432.CCR-08-0640", "volume": "15", "author": "JJ Gorski", "year": "2009", "unstructured": "Gorski JJ, Kennedy RD, Hosey AM, Harkin DP: The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res. 2009, 15: 1514-1518. 10.1158/1078-0432.CCR-08-0640.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR18", "doi-asserted-by": "publisher", "first-page": "362", "DOI": "10.1016/S0959-8049(97)89007-7", "volume": "33", "author": "OT Johannsson", "year": "1997", "unstructured": "Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997, 33: 362-371. 10.1016/S0959-8049(97)89007-7.", "journal-title": "Eur J Cancer"}, {"key": "2755_CR19", "doi-asserted-by": "publisher", "first-page": "310", "DOI": "10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W", "volume": "83", "author": "N Loman", "year": "1998", "unstructured": "Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998, 83: 310-319. 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W.", "journal-title": "Cancer"}, {"key": "2755_CR20", "doi-asserted-by": "publisher", "first-page": "R12", "DOI": "10.1186/bcr2478", "volume": "12", "author": "N Tung", "year": "2010", "unstructured": "Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ: Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010, 12: R12-10.1186/bcr2478.", "journal-title": "Breast Cancer Res"}, {"key": "2755_CR21", "doi-asserted-by": "crossref", "first-page": "CRA501", "DOI": "10.1200/jco.2009.27.18_suppl.cra501", "volume": "27", "author": "A Tutt", "year": "2009", "unstructured": "Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Journal of Clinical Oncology. 2009, 27: CRA501-", "journal-title": "Journal of Clinical Oncology"}, {"key": "2755_CR22", "doi-asserted-by": "publisher", "first-page": "339", "DOI": "10.1007/s10689-009-9240-1", "volume": "8", "author": "AM Dworkin", "year": "2009", "unstructured": "Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE: Methylation not a frequent \"second hit\" in tumors with germline BRCA mutations. Fam Cancer. 2009, 8: 339-346. 10.1007/s10689-009-9240-1.", "journal-title": "Fam Cancer"}, {"key": "2755_CR23", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1002/ijc.10337", "volume": "99", "author": "A Osorio", "year": "2002", "unstructured": "Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldes T, Benitez J: Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 2002, 99: 305-309. 10.1002/ijc.10337.", "journal-title": "Int J Cancer"}, {"key": "2755_CR24", "doi-asserted-by": "publisher", "first-page": "663", "DOI": "10.1158/0008-5472.CAN-08-1560", "volume": "69", "author": "E Manie", "year": "2009", "unstructured": "Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Th\u00e9 H, Stoppa-Lyonnet D, Stern MH: High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 2009, 69: 663-671. 10.1158/0008-5472.CAN-08-1560.", "journal-title": "Cancer Res"}, {"key": "2755_CR25", "doi-asserted-by": "publisher", "first-page": "5463", "DOI": "10.1073/pnas.74.12.5463", "volume": "74", "author": "F Sanger", "year": "1977", "unstructured": "Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977, 74: 5463-5467. 10.1073/pnas.74.12.5463.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2755_CR26", "author": "S Rozen", "first-page": "365", "year": "2000", "unstructured": "Rozen S, Skaletsky HJ: Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Edited by: Krawetz S, Misener S. 2000, Totowa, NJ: Humana Press, 365-386.", "volume-title": "Bioinformatics Methods and Protocols: Methods in Molecular Biology"}, {"key": "2755_CR27", "unstructured": "Integrated DNA Technologies. [ http://www.idtdna.com ]"}, {"key": "2755_CR28", "doi-asserted-by": "publisher", "first-page": "3235", "DOI": "10.1093/nar/25.16.3235", "volume": "25", "author": "J Brownie", "year": "1997", "unstructured": "Brownie J, Shawcross S, Theaker J, Whitcombe D, Ferrie R, Newton C, Little S: The elimination of primer-dimer accumulation in PCR. Nucleic Acids Res. 1997, 25: 3235-3241. 10.1093/nar/25.16.3235.", "journal-title": "Nucleic Acids Res"}, {"key": "2755_CR29", "unstructured": "Agencourt protocols: AMPure. [ http://www.beckmangenomics.com/documents/products/ampurexp/AMPureXPProtocol_000387v001.pdf ]"}, {"key": "2755_CR30", "unstructured": "Agencourt protocols: CleanSEQ. [ http://www.beckmangenomics.com/documents/products/cleanseq/Agencourt_CleanSEQ_Protocol.pdf ]"}, {"key": "2755_CR31", "doi-asserted-by": "publisher", "first-page": "179", "DOI": "10.1007/s10549-004-7603-8", "volume": "91", "author": "E Matros", "year": "2005", "unstructured": "Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL: BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005, 91: 179-186. 10.1007/s10549-004-7603-8.", "journal-title": "Breast Cancer Res Treat"}, {"key": "2755_CR32", "doi-asserted-by": "publisher", "first-page": "1680", "DOI": "10.1073/pnas.0711613105", "volume": "105", "author": "S Liu", "year": "2008", "unstructured": "Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS: BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA. 2008, 105: 1680-1685. 10.1073/pnas.0711613105.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2755_CR33", "doi-asserted-by": "publisher", "first-page": "503", "DOI": "10.1038/sj.bjc.6690722", "volume": "81", "author": "R Gonzalez", "year": "1999", "unstructured": "Gonzalez R, Silva JM, Dominguez G, Garcia JM, Martinez G, Vargas J, Provencio M, Espana P, Bonilla F: Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br J Cancer. 1999, 81: 503-509. 10.1038/sj.bjc.6690722.", "journal-title": "Br J Cancer"}, {"key": "2755_CR34", "doi-asserted-by": "publisher", "first-page": "64", "DOI": "10.1158/0008-5472.CAN-03-2570", "volume": "64", "author": "ZC Wang", "year": "2004", "unstructured": "Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A: Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004, 64: 64-71. 10.1158/0008-5472.CAN-03-2570.", "journal-title": "Cancer Res"}, {"key": "2755_CR35", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1016/j.ccr.2006.01.013", "volume": "9", "author": "AL Richardson", "year": "2006", "unstructured": "Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006, 9: 121-132. 10.1016/j.ccr.2006.01.013.", "journal-title": "Cancer Cell"}, {"key": "2755_CR36", "doi-asserted-by": "publisher", "first-page": "1870", "DOI": "10.1093/annonc/mdn409", "volume": "19", "author": "KP Suijkerbuijk", "year": "2008", "unstructured": "Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ: Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol. 2008, 19: 1870-1874. 10.1093/annonc/mdn409.", "journal-title": "Ann Oncol"}, {"key": "2755_CR37", "doi-asserted-by": "publisher", "first-page": "2126", "DOI": "10.1038/sj.onc.1210014", "volume": "26", "author": "NC Turner", "year": "2007", "unstructured": "Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007, 26: 2126-2132. 10.1038/sj.onc.1210014.", "journal-title": "Oncogene"}, {"key": "2755_CR38", "doi-asserted-by": "publisher", "first-page": "901", "DOI": "10.1158/1055-9965.EPI-08-0875", "volume": "18", "author": "SN Vasilatos", "year": "2009", "unstructured": "Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL: CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2009, 18: 901-914. 10.1158/1055-9965.EPI-08-0875.", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"key": "2755_CR39", "doi-asserted-by": "publisher", "first-page": "195", "DOI": "10.1007/s10549-008-0121-3", "volume": "116", "author": "T Kontorovich", "year": "2009", "unstructured": "Kontorovich T, Cohen Y, Nir U, Friedman E: Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat. 2009, 116: 195-200. 10.1007/s10549-008-0121-3.", "journal-title": "Breast Cancer Res Treat"}, {"key": "2755_CR40", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1097/01.pas.0000213351.49767.0f", "volume": "31", "author": "AL Bane", "year": "2007", "unstructured": "Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP, for the Breast Cancer Family Registry: BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007, 31: 121-128. 10.1097/01.pas.0000213351.49767.0f.", "journal-title": "Am J Surg Pathol"}, {"key": "2755_CR41", "doi-asserted-by": "publisher", "first-page": "2302", "DOI": "10.1158/1078-0432.CCR-08-2132", "volume": "15", "author": "EA Rakha", "year": "2009", "unstructured": "Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009, 15: 2302-2310. 10.1158/1078-0432.CCR-08-2132.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR42", "first-page": "3606", "volume": "9", "author": "J Palacios", "year": "2003", "unstructured": "Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J: Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003, 9: 3606-3614.", "journal-title": "Clin Cancer Res"}, {"key": "2755_CR43", "doi-asserted-by": "publisher", "first-page": "130", "DOI": "10.1073/pnas.98.1.130", "volume": "98", "author": "C Beger", "year": "2001", "unstructured": "Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F: Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA. 2001, 98: 130-135. 10.1073/pnas.98.1.130.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "2755_CR44", "doi-asserted-by": "publisher", "first-page": "907", "DOI": "10.1038/nm.2000", "volume": "15", "author": "E Lim", "year": "2009", "unstructured": "Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009, 15: 907-913. 10.1038/nm.2000.", "journal-title": "Nat Med"}, {"key": "2755_CR45", "doi-asserted-by": "publisher", "first-page": "1467", "DOI": "10.1126/science.1130471", "volume": "314", "author": "AJ Poole", "year": "2006", "unstructured": "Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006, 314: 1467-1470. 10.1126/science.1130471.", "journal-title": "Science"}, {"key": "2755_CR46", "doi-asserted-by": "publisher", "first-page": "229", "DOI": "10.1016/j.stem.2009.08.007", "volume": "5", "author": "C Ginestier", "year": "2009", "unstructured": "Ginestier C, Liu S, Wicha MS: Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell. 2009, 5: 229-230. 10.1016/j.stem.2009.08.007.", "journal-title": "Cell Stem Cell"}, {"key": "2755_CR47", "doi-asserted-by": "publisher", "first-page": "235", "DOI": "10.1016/S0140-6736(10)60892-6", "volume": "376", "author": "A Tutt", "year": "2010", "unstructured": "Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010, 376: 235-244. 10.1016/S0140-6736(10)60892-6.", "journal-title": "Lancet"}, {"key": "2755_CR48", "doi-asserted-by": "publisher", "first-page": "359", "DOI": "10.1007/s10549-008-0128-9", "volume": "115", "author": "T Byrski", "year": "2009", "unstructured": "Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009, 115: 359-363. 10.1007/s10549-008-0128-9.", "journal-title": "Breast Cancer Res Treat"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr2776.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr2776/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr2776.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 6]], "date-time": "2019-06-06T09:36:01Z", "timestamp": 1559813761000}, "score": 31.350454, "issued": {"date-parts": [[2010, 11, 16]]}, "references-count": 48, "journal-issue": {"published-print": {"date-parts": [[2010, 12]]}, "issue": "6"}, "alternative-id": ["2755"], "URL": "http://dx.doi.org/10.1186/bcr2776", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "article-number": "R95"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T18:16:31Z", "timestamp": 1575224191824}, "publisher-location": "Cham", "reference-count": 97, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319699790", "type": "print"}, {"value": "9783319699806", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 11, 1]], "date-time": "2017-11-01T00:00:00Z", "timestamp": 1509494400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018]]}, "DOI": "10.1007/978-3-319-69980-6_8", "type": "book-chapter", "created": {"date-parts": [[2018, 1, 11]], "date-time": "2018-01-11T09:33:47Z", "timestamp": 1515663227000}, "page": "95-116", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Management of Metastatic Triple-Negative Breast Cancer"], "prefix": "10.1007", "author": [{"given": "Anne P.", "family": "O\u2019Dea", "sequence": "first", "affiliation": []}, {"given": "Priyanka", "family": "Sharma", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 11, 1]]}, "reference": [{"key": "8_CR1", "unstructured": "Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721\u20138.", "DOI": "10.1002/cncr.22618", "doi-asserted-by": "crossref"}, {"key": "8_CR2", "unstructured": "Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195\u20137.", "DOI": "10.1200/JOP.777003", "doi-asserted-by": "crossref"}, {"key": "8_CR3", "unstructured": "Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.", "DOI": "10.1200/JCO.2013.50.9984", "doi-asserted-by": "crossref"}, {"key": "8_CR4", "unstructured": "Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975\u20132011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.", "DOI": "10.1093/jnci/djv048", "doi-asserted-by": "crossref"}, {"issue": "8", "key": "8_CR5", "doi-asserted-by": "crossref", "first-page": "2329", "DOI": "10.1158/1078-0432.CCR-06-1109", "volume": "13", "author": "LA Carey", "year": "2007", "unstructured": "Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329\u201334.", "journal-title": "Clin Cancer Res"}, {"issue": "15 Pt 1", "key": "8_CR6", "doi-asserted-by": "crossref", "first-page": "4429", "DOI": "10.1158/1078-0432.CCR-06-3045", "volume": "13", "author": "R Dent", "year": "2007", "unstructured": "Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334.", "journal-title": "Clin Cancer Res"}, {"issue": "8", "key": "8_CR7", "doi-asserted-by": "crossref", "first-page": "1275", "DOI": "10.1200/JCO.2007.14.4147", "volume": "26", "author": "C Liedtke", "year": "2008", "unstructured": "Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "8_CR8", "doi-asserted-by": "crossref", "first-page": "821", "DOI": "10.6004/jnccn.2012.0086", "volume": "10", "author": "RW Carlson", "year": "2012", "unstructured": "Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10(7):821\u20139.", "journal-title": "J Natl Compr Cancer Netw"}, {"issue": "3", "key": "8_CR9", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1007/s10549-013-2825-2", "volume": "143", "author": "EM Duenas de", "year": "2014", "unstructured": "de Duenas EM, Hernandez AL, Zotano AG, Carrion RM, Lopez-Muniz JI, Novoa SA, et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat. 2014;143(3):507\u201315.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "11", "key": "8_CR10", "doi-asserted-by": "crossref", "first-page": "1184", "DOI": "10.1136/jcp.2007.047720", "volume": "61", "author": "G Bussolati", "year": "2008", "unstructured": "Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol. 2008;61(11):1184\u201392.", "journal-title": "J Clin Pathol"}, {"issue": "4", "key": "8_CR11", "doi-asserted-by": "crossref", "first-page": "297", "DOI": "10.1097/PAI.0000000000000082", "volume": "23", "author": "JR Gruchy", "year": "2015", "unstructured": "Gruchy JR, Barnes PJ, Dakin Hache KA. CytoLyt(R) fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol. 2015;23(4):297\u2013302.", "journal-title": "Appl Immunohistochem Mol Morphol"}, {"issue": "5", "key": "8_CR12", "doi-asserted-by": "crossref", "first-page": "1368", "DOI": "10.1158/1078-0432.CCR-07-1658", "volume": "14", "author": "MC Cheang", "year": "2008", "unstructured": "Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368\u201376.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "8_CR13", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1007/s10549-008-0086-2", "volume": "115", "author": "R Dent", "year": "2009", "unstructured": "Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423\u20138.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "8", "key": "8_CR14", "doi-asserted-by": "crossref", "first-page": "724", "DOI": "10.1056/NEJMoa1413513", "volume": "372", "author": "SM Swain", "year": "2015", "unstructured": "Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.", "journal-title": "N Engl J Med"}, {"issue": "33", "key": "8_CR15", "doi-asserted-by": "crossref", "first-page": "5210", "DOI": "10.1200/JCO.2007.12.6557", "volume": "25", "author": "ES Thomas", "year": "2007", "unstructured": "Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "8_CR16", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.3816/CBC.2008.n.026", "volume": "8", "author": "C Bunnell", "year": "2008", "unstructured": "Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008;8(3):234\u201341.", "journal-title": "Clin Breast Cancer"}, {"issue": "5", "key": "8_CR17", "doi-asserted-by": "crossref", "first-page": "1082", "DOI": "10.1158/1078-0432.CCR-10-2560", "volume": "17", "author": "AM Gonzalez-Angulo", "year": "2011", "unstructured": "Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082\u20139.", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "8_CR18", "doi-asserted-by": "crossref", "first-page": "2787", "DOI": "10.1002/cncr.26576", "volume": "118", "author": "AR Hartman", "year": "2012", "unstructured": "Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787\u201395.", "journal-title": "Cancer"}, {"issue": "3", "key": "8_CR19", "doi-asserted-by": "crossref", "first-page": "707", "DOI": "10.1007/s10549-014-2980-0", "volume": "145", "author": "P Sharma", "year": "2014", "unstructured": "Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707\u201314.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "4", "key": "8_CR20", "doi-asserted-by": "crossref", "first-page": "304", "DOI": "10.1200/JCO.2014.57.1414", "volume": "33", "author": "FJ Couch", "year": "2015", "unstructured": "Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304\u201311.", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "8_CR21", "doi-asserted-by": "crossref", "first-page": "3439", "DOI": "10.1200/JCO.1998.16.10.3439", "volume": "16", "author": "R Fossati", "year": "1998", "unstructured": "Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16(10):3439\u201360.", "journal-title": "J Clin Oncol"}, {"key": "8_CR22", "first-page": "CD008792", "volume": "12", "author": "RF Dear", "year": "2013", "unstructured": "Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2013;12:CD008792.", "journal-title": "Cochrane Database Syst Rev"}, {"key": "8_CR23", "unstructured": "Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009(2):Cd003372.", "DOI": "10.1002/14651858.CD003372.pub3", "doi-asserted-by": "crossref"}, {"issue": "16", "key": "8_CR24", "doi-asserted-by": "crossref", "first-page": "2144", "DOI": "10.1200/JCO.2010.31.5374", "volume": "29", "author": "A Gennari", "year": "2011", "unstructured": "Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "14", "key": "8_CR25", "doi-asserted-by": "crossref", "first-page": "1732", "DOI": "10.1200/JCO.2012.45.2490", "volume": "31", "author": "YH Park", "year": "2013", "unstructured": "Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013;31(14):1732\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "16", "key": "8_CR26", "doi-asserted-by": "crossref", "first-page": "1663", "DOI": "10.1056/NEJMoa0707056", "volume": "358", "author": "JA Sparano", "year": "2008", "unstructured": "Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663\u201371.", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "8_CR27", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1016/j.ctrv.2009.10.006", "volume": "36", "author": "D Mauri", "year": "2010", "unstructured": "Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2010;36(1):69\u201374.", "journal-title": "Cancer Treat Rev"}, {"issue": "25", "key": "8_CR28", "doi-asserted-by": "crossref", "first-page": "6019", "DOI": "10.1200/JCO.2005.11.013", "volume": "23", "author": "NK Ibrahim", "year": "2005", "unstructured": "Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23(25):6019\u201326.", "journal-title": "J Clin Oncol"}, {"issue": "22", "key": "8_CR29", "doi-asserted-by": "crossref", "first-page": "3611", "DOI": "10.1200/JCO.2008.18.5397", "volume": "27", "author": "WJ Gradishar", "year": "2009", "unstructured": "Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Cin Oncol. 2009;27(22):3611\u20139.", "journal-title": "J Cin Oncol"}, {"issue": "21", "key": "8_CR30", "doi-asserted-by": "crossref", "first-page": "2361", "DOI": "10.1200/JCO.2014.59.5298", "volume": "33", "author": "HS Rugo", "year": "2015", "unstructured": "Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound Nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "8_CR31", "doi-asserted-by": "crossref", "first-page": "440", "DOI": "10.1093/annonc/mdh097", "volume": "15", "author": "ME O\u2019Brien", "year": "2004", "unstructured": "O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139.", "journal-title": "Ann Oncol"}, {"issue": "2 Supplement", "key": "8_CR32", "doi-asserted-by": "crossref", "first-page": "3057", "DOI": "10.1158/0008-5472.SABCS-3057", "volume": "69", "author": "H Rugo", "year": "2009", "unstructured": "Rugo H, Roche H, Thomas E, Blackwell K, Chung H, Lerzo G, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res. 2009;69(2 Supplement):3057.", "journal-title": "Cancer Res"}, {"issue": "18_suppl", "key": "8_CR33", "first-page": "1013", "volume": "25", "author": "G Sledge", "year": "2007", "unstructured": "Sledge G, Miller K, Moisa C, Gradishar W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol. 2007;25(18_suppl):1013.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "8_CR34", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.1007/s10549-004-2468-4", "volume": "90", "author": "SY Rha", "year": "2005", "unstructured": "Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90(3):215\u201321.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "1", "key": "8_CR35", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1159/000048240", "volume": "62", "author": "M Blackstein", "year": "2002", "unstructured": "Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62(1):2\u20138.", "journal-title": "Oncology"}, {"issue": "6", "key": "8_CR36", "doi-asserted-by": "crossref", "first-page": "899", "DOI": "10.1093/annonc/mdi181", "volume": "16", "author": "O Feher", "year": "2005", "unstructured": "Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005;16(6):899\u2013908.", "journal-title": "Ann Oncol"}, {"issue": "4", "key": "8_CR37", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1023/A:1008364222793", "volume": "10", "author": "C Vogel", "year": "1999", "unstructured": "Vogel C, O\u2019Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999;10(4):397\u2013402.", "journal-title": "Ann Oncol"}, {"issue": "3", "key": "8_CR38", "doi-asserted-by": "crossref", "first-page": "219", "DOI": "10.1016/S1470-2045(07)70041-4", "volume": "8", "author": "M Martin", "year": "2007", "unstructured": "Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219\u201325.", "journal-title": "Lancet Oncol"}, {"key": "8_CR39", "unstructured": "Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O\u2019Rourke M, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995;13(10):2567\u201374.", "DOI": "10.1200/JCO.1995.13.10.2567", "doi-asserted-by": "crossref"}, {"issue": "7", "key": "8_CR40", "doi-asserted-by": "crossref", "first-page": "1086", "DOI": "10.1158/1535-7163.MCT-04-0345", "volume": "4", "author": "MA Jordan", "year": "2005", "unstructured": "Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086\u201395.", "journal-title": "Mol Cancer Ther"}, {"issue": "3", "key": "8_CR41", "first-page": "1013", "volume": "61", "author": "MJ Towle", "year": "2001", "unstructured": "Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61(3):1013\u201321.", "journal-title": "Cancer Res"}, {"issue": "7", "key": "8_CR42", "doi-asserted-by": "crossref", "first-page": "2003", "DOI": "10.1158/1535-7163.MCT-08-0095", "volume": "7", "author": "T Okouneva", "year": "2008", "unstructured": "Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008;7(7):2003\u201311.", "journal-title": "Mol Cancer Ther"}, {"key": "8_CR43", "unstructured": "Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (London, England). 2011;377(9769):914\u201323.", "DOI": "10.1016/S0140-6736(11)60070-6", "doi-asserted-by": "crossref"}, {"issue": "6", "key": "8_CR44", "doi-asserted-by": "crossref", "first-page": "594", "DOI": "10.1200/JCO.2013.52.4892", "volume": "33", "author": "PA Kaufman", "year": "2015", "unstructured": "Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "8_CR45", "doi-asserted-by": "crossref", "first-page": "553", "DOI": "10.1007/s10549-014-3144-y", "volume": "148", "author": "C Twelves", "year": "2014", "unstructured": "Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553\u201361.", "journal-title": "Breast Cancer Res Treat"}, {"key": "8_CR46", "unstructured": "Altmann K-H, Wartmann M, O\u2019Reilly T. Epothilones and related structures\u00a0\u2013 a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79\u201391.", "DOI": "10.1016/S0304-419X(00)00009-3", "doi-asserted-by": "crossref"}, {"issue": "6", "key": "8_CR47", "doi-asserted-by": "crossref", "first-page": "2904", "DOI": "10.1073/pnas.040546297", "volume": "97", "author": "P Giannakakou", "year": "2000", "unstructured": "Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci. 2000;97(6):2904\u20139.", "journal-title": "Proc Natl Acad Sci"}, {"key": "8_CR48", "unstructured": "Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122(2):409\u201318.", "DOI": "10.1007/s10549-010-0901-4", "doi-asserted-by": "crossref"}, {"issue": "20", "key": "8_CR49", "doi-asserted-by": "crossref", "first-page": "3256", "DOI": "10.1200/JCO.2009.24.4244", "volume": "28", "author": "JA Sparano", "year": "2010", "unstructured": "Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256\u201363.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "8_CR50", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1007/s10549-010-0824-0", "volume": "121", "author": "EA Perez", "year": "2010", "unstructured": "Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010;121(2):261\u201371.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "23", "key": "8_CR51", "doi-asserted-by": "crossref", "first-page": "3421", "DOI": "10.1200/JCO.2006.10.0784", "volume": "25", "author": "N Denduluri", "year": "2007", "unstructured": "Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007;25(23):3421\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "8_CR52", "doi-asserted-by": "crossref", "first-page": "2726", "DOI": "10.1200/JCO.2005.10.024", "volume": "23", "author": "JA Low", "year": "2005", "unstructured": "Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23(12):2726\u201334.", "journal-title": "J Clin Oncol"}, {"issue": "13", "key": "8_CR53", "doi-asserted-by": "crossref", "first-page": "2163", "DOI": "10.1200/JCO.2008.17.4839", "volume": "27", "author": "HK Chew", "year": "2009", "unstructured": "Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27(13):2163\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "8_CR54", "first-page": "553", "volume": "29", "author": "JP Delord", "year": "2009", "unstructured": "Delord JP, Puozzo C, Lefresne F, Bugat R. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. Anticancer Res. 2009;29(2):553\u201360.", "journal-title": "Anticancer Res"}, {"issue": "2", "key": "8_CR55", "doi-asserted-by": "crossref", "first-page": "178", "DOI": "10.3816/CBC.2008.n.019", "volume": "8", "author": "D Loesch", "year": "2008", "unstructured": "Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178\u201386.", "journal-title": "Clin Breast Cancer"}, {"issue": "5", "key": "8_CR56", "doi-asserted-by": "crossref", "first-page": "425", "DOI": "10.3816/CBC.2008.n.051", "volume": "8", "author": "DA Yardley", "year": "2008", "unstructured": "Yardley DA, Burris HA, Simons L, Spigel DR, Greco EA, Barton JH, et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(5):425\u201331.", "journal-title": "Clin Breast Cancer"}, {"key": "8_CR57", "unstructured": "Yardley D, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, et al. nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial [abstract]. Cancer Res. 2017;77(4 Suppl):P5-15-03.", "DOI": "10.1158/1538-7445.SABCS16-P5-15-03", "doi-asserted-by": "crossref"}, {"issue": "12", "key": "8_CR58", "doi-asserted-by": "crossref", "first-page": "2855", "DOI": "10.1158/1078-0432.CCR-15-2137", "volume": "22", "author": "ET Rodler", "year": "2016", "unstructured": "Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, et al. Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res. 2016;22(12):2855\u201364.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "8_CR59", "doi-asserted-by": "crossref", "first-page": "427", "DOI": "10.1007/s10549-010-1002-0", "volume": "123", "author": "C Lobo", "year": "2010", "unstructured": "Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):427\u201335.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "6", "key": "8_CR60", "doi-asserted-by": "crossref", "first-page": "416", "DOI": "10.1016/j.clbc.2013.08.003", "volume": "13", "author": "E Hamilton", "year": "2013", "unstructured": "Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013;13(6):416\u201320.", "journal-title": "Clin Breast Cancer"}, {"issue": "3", "key": "8_CR61", "doi-asserted-by": "crossref", "first-page": "449", "DOI": "10.1093/annonc/mdn661", "volume": "20", "author": "V Roy", "year": "2009", "unstructured": "Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 2009;20(3):449\u201353.", "journal-title": "Ann Oncol"}, {"issue": "12", "key": "8_CR62", "doi-asserted-by": "crossref", "first-page": "2812", "DOI": "10.1200/JCO.2002.09.002", "volume": "20", "author": "J O\u2019Shaughnessy", "year": "2002", "unstructured": "O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002;20(12):2812\u201323.", "journal-title": "J Clin Oncol"}, {"issue": "16", "key": "8_CR63", "doi-asserted-by": "crossref", "first-page": "8109", "DOI": "10.1158/0008-5472.CAN-06-0140", "volume": "66", "author": "N McCabe", "year": "2006", "unstructured": "McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109\u201315.", "journal-title": "Cancer Res"}, {"issue": "7035", "key": "8_CR64", "doi-asserted-by": "crossref", "first-page": "917", "DOI": "10.1038/nature03445", "volume": "434", "author": "H Farmer", "year": "2005", "unstructured": "Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.", "journal-title": "Nature"}, {"issue": "7035", "key": "8_CR65", "doi-asserted-by": "crossref", "first-page": "913", "DOI": "10.1038/nature03443", "volume": "434", "author": "HE Bryant", "year": "2005", "unstructured": "Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.", "journal-title": "Nature"}, {"issue": "2", "key": "8_CR66", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa0900212", "volume": "361", "author": "PC Fong", "year": "2009", "unstructured": "Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.", "journal-title": "N Engl J Med"}, {"issue": "9737", "key": "8_CR67", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1016/S0140-6736(10)60893-8", "volume": "376", "author": "MW Audeh", "year": "2010", "unstructured": "Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (London, England). 2010;376(9737):245\u201351.", "journal-title": "Lancet (London, England)"}, {"issue": "9737", "key": "8_CR68", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1016/S0140-6736(10)60892-6", "volume": "376", "author": "A Tutt", "year": "2010", "unstructured": "Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England). 2010;376(9737):235\u201344.", "journal-title": "Lancet (London, England)"}, {"key": "8_CR69", "unstructured": "Mina LA, Ramanathan RK, Wainberg ZA, Byers LA, Chugh R, Sachdev JC, et al. BMN673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA1 and 2 mutations [abstract]. Cancer Res. 2013;73(24 Suppl):P2-09-02", "DOI": "10.1158/0008-5472.SABCS13-P2-09-02", "doi-asserted-by": "crossref"}, {"issue": "9", "key": "8_CR70", "doi-asserted-by": "crossref", "first-page": "882", "DOI": "10.1016/S1470-2045(13)70240-7", "volume": "14", "author": "SK Sandhu", "year": "2013", "unstructured": "Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882\u201392.", "journal-title": "Lancet Oncol"}, {"issue": "3", "key": "8_CR71", "doi-asserted-by": "crossref", "first-page": "244", "DOI": "10.1200/JCO.2014.56.2728", "volume": "33", "author": "B Kaufman", "year": "2015", "unstructured": "Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244\u201350.", "journal-title": "J Clin Oncol"}, {"key": "8_CR72", "doi-asserted-by": "crossref", "first-page": "523", "DOI": "10.1056/NEJMoa1706450", "volume": "377", "author": "M Robson", "year": "2017", "unstructured": "Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.", "journal-title": "N Engl J Med"}, {"key": "8_CR73", "unstructured": "Tutt A, Cheang M, Kilburn L, Tovey H, Gillett C, Pinder S, et al. BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) [abstract]. Cancer Res. 2017;77(4 Suppl):S6-01."}, {"issue": "18", "key": "8_CR74", "doi-asserted-by": "crossref", "first-page": "5003", "DOI": "10.1158/1078-0432.CCR-13-1391", "volume": "19", "author": "Y Shen", "year": "2013", "unstructured": "Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003\u201315.", "journal-title": "Clin Cancer Res"}, {"issue": "15_suppl", "key": "8_CR75", "doi-asserted-by": "crossref", "first-page": "1021", "DOI": "10.1200/jco.2014.32.15_suppl.1021", "volume": "32", "author": "G Somlo", "year": "2014", "unstructured": "Somlo G, Frankel PH, Luu TH, Ma C, Arun B, Garcia A, et al. Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96. J Clin Oncol. 2014;32(15_suppl):1021.", "journal-title": "J Clin Oncol"}, {"key": "8_CR76", "unstructured": "Turner N, Telli ML, Rugo HS, Mailiez A, Ettl J, Grischke EM, et al., editors. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). ASCO Annual Meeting 2017; Chicago, IL.", "DOI": "10.1200/JCO.2017.35.15_suppl.1007", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "8_CR77", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.3816/CBC.2008.n.035", "volume": "8", "author": "IL Wapnir", "year": "2008", "unstructured": "Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, et al. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008;8(3):287\u201392.", "journal-title": "Clin Breast Cancer"}, {"issue": "2", "key": "8_CR78", "doi-asserted-by": "crossref", "first-page": "156", "DOI": "10.1016/S1470-2045(13)70589-8", "volume": "15", "author": "S Aebi", "year": "2014", "unstructured": "Aebi S, Gelber S, Anderson SJ, Lang I, Robidoux A, Martin M, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15(2):156\u201363.", "journal-title": "Lancet Oncol"}, {"issue": "19", "key": "8_CR79", "doi-asserted-by": "crossref", "first-page": "4652", "DOI": "10.1002/cncr.27434", "volume": "118", "author": "S Dawood", "year": "2012", "unstructured": "Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012;118(19):4652\u20139.", "journal-title": "Cancer"}, {"issue": "10", "key": "8_CR80", "doi-asserted-by": "crossref", "first-page": "2638", "DOI": "10.1002/cncr.23930", "volume": "113", "author": "NU Lin", "year": "2008", "unstructured": "Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638\u201345.", "journal-title": "Cancer"}, {"issue": "4", "key": "8_CR81", "doi-asserted-by": "crossref", "first-page": "621", "DOI": "10.1093/annonc/mdn682", "volume": "20", "author": "S Dawood", "year": "2009", "unstructured": "Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20(4):621\u20137.", "journal-title": "Ann Oncol"}, {"issue": "11", "key": "8_CR82", "doi-asserted-by": "crossref", "first-page": "2359", "DOI": "10.1002/cncr.23468", "volume": "112", "author": "AF Eichler", "year": "2008", "unstructured": "Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008;112(11):2359\u201367.", "journal-title": "Cancer"}, {"issue": "1", "key": "8_CR83", "doi-asserted-by": "crossref", "first-page": "R20", "DOI": "10.1186/bcr1870", "volume": "10", "author": "BH Nam", "year": "2008", "unstructured": "Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10(1):R20.", "journal-title": "Breast Cancer Res"}, {"issue": "3", "key": "8_CR84", "doi-asserted-by": "crossref", "first-page": "557", "DOI": "10.1007/s10549-014-3039-y", "volume": "146", "author": "C Anders", "year": "2014", "unstructured": "Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014;146(3):557\u201366.", "journal-title": "Breast Cancer Res Treat"}, {"issue": "4", "key": "8_CR85", "doi-asserted-by": "crossref", "first-page": "920", "DOI": "10.1158/1535-7163.MCT-14-0474", "volume": "14", "author": "O Karginova", "year": "2015", "unstructured": "Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, et al. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer. Mol Cancer Ther. 2015;14(4):920\u201330.", "journal-title": "Mol Cancer Ther"}, {"issue": "6", "key": "8_CR86", "doi-asserted-by": "crossref", "first-page": "1125", "DOI": "10.1007/s00280-014-2577-7", "volume": "74", "author": "U Hoch", "year": "2014", "unstructured": "Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74(6):1125\u201337.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "8_CR87", "unstructured": "Perez EA, Awada A, O\u2019Shaughnessy J, Rugo HS, Twelves C, Im S-A, et al. Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(15):1556\u201368.", "DOI": "10.1016/S1470-2045(15)00332-0", "doi-asserted-by": "crossref"}, {"issue": "16", "key": "8_CR88", "doi-asserted-by": "crossref", "first-page": "1655", "DOI": "10.1056/NEJMra030831", "volume": "350", "author": "GD Roodman", "year": "2004", "unstructured": "Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364.", "journal-title": "N Engl J Med"}, {"issue": "9", "key": "8_CR89", "doi-asserted-by": "crossref", "first-page": "1221", "DOI": "10.1200/JCO.2010.32.5209", "volume": "29", "author": "CH Poznak Van", "year": "2011", "unstructured": "Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "8_CR90", "doi-asserted-by": "crossref", "first-page": "906", "DOI": "10.1001/jamaoncol.2016.6316", "volume": "3", "author": "GN Hortobagyi", "year": "2017", "unstructured": "Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017;3(7):906\u201312.", "journal-title": "JAMA Oncol"}, {"issue": "6797", "key": "8_CR91", "doi-asserted-by": "crossref", "first-page": "747", "DOI": "10.1038/35021093", "volume": "406", "author": "CM Perou", "year": "2000", "unstructured": "Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.", "journal-title": "Nature"}, {"issue": "7", "key": "8_CR92", "doi-asserted-by": "crossref", "first-page": "2750", "DOI": "10.1172/JCI45014", "volume": "121", "author": "BD Lehmann", "year": "2011", "unstructured": "Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.", "journal-title": "J Clin Invest"}, {"issue": "1", "key": "8_CR93", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1016/j.molonc.2010.11.003", "volume": "5", "author": "A Prat", "year": "2011", "unstructured": "Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5\u201323.", "journal-title": "Mol Oncol"}, {"issue": "7403", "key": "8_CR94", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1038/nature10933", "volume": "486", "author": "SP Shah", "year": "2012", "unstructured": "Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395\u20139.", "journal-title": "Nature"}, {"issue": "6", "key": "8_CR95", "doi-asserted-by": "crossref", "first-page": "e0157368", "DOI": "10.1371/journal.pone.0157368", "volume": "11", "author": "BD Lehmann", "year": "2016", "unstructured": "Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368.", "journal-title": "PLoS One"}, {"issue": "1", "key": "8_CR96", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1186/s12885-015-2026-y", "volume": "16", "author": "BZ Ring", "year": "2016", "unstructured": "Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, et al. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 2016;16(1):1\u20138.", "journal-title": "BMC Cancer"}, {"key": "8_CR97", "unstructured": "The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.", "DOI": "10.1038/nature11412", "doi-asserted-by": "crossref"}], "container-title": ["Triple-Negative Breast Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-69980-6_8", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T07:27:07Z", "timestamp": 1570606027000}, "score": 31.25392, "issued": {"date-parts": [[2017, 11, 1]]}, "ISBN": ["9783319699790", "9783319699806"], "references-count": 97, "URL": "http://dx.doi.org/10.1007/978-3-319-69980-6_8", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T20:07:38Z", "timestamp": 1575403658581}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clin Cancer Res"], "published-print": {"date-parts": [[2014, 2, 1]]}, "DOI": "10.1158/1078-0432.ccr-13-0225", "type": "journal-article", "created": {"date-parts": [[2013, 11, 23]], "date-time": "2013-11-23T02:35:10Z", "timestamp": 1385174110000}, "page": "540-547", "source": "Crossref", "is-referenced-by-count": 66, "title": ["Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?"], "prefix": "10.1158", "volume": "20", "author": [{"given": "Peter", "family": "Bouwman", "sequence": "first", "affiliation": []}, {"given": "Jos", "family": "Jonkers", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2013, 11, 22]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-13-0225", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 1]], "date-time": "2017-08-01T13:49:56Z", "timestamp": 1501595396000}, "score": 30.897675, "issued": {"date-parts": [[2013, 11, 22]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 2, 2]]}, "published-print": {"date-parts": [[2014, 2, 1]]}, "issue": "3"}, "alternative-id": ["10.1158/1078-0432.CCR-13-0225"], "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-13-0225", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T11:44:00Z", "timestamp": 1574509440447}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 12, 15]]}, "DOI": "10.1158/0008-5472.sabcs10-p6-04-04", "type": "proceedings-article", "created": {"date-parts": [[2011, 4, 27]], "date-time": "2011-04-27T13:50:42Z", "timestamp": 1303912242000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P6-04-04: Hypoxia Is Associated with Somatic Loss of BRCA1 Protein and Pathway Activity in Triple Negative Breast Cancer"], "prefix": "10.1158", "author": [{"given": "V", "family": "Neumeister", "sequence": "first", "affiliation": []}, {"given": "J", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Lindner", "sequence": "additional", "affiliation": []}, {"given": "C", "family": "Sullivan", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Glazer", "sequence": "additional", "affiliation": []}, {"given": "DP", "family": "Tuck", "sequence": "additional", "affiliation": []}, {"given": "DL", "family": "Rimm", "sequence": "additional", "affiliation": []}, {"given": "LN.", "family": "Harris", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 6]]}, "event": {"name": "Abstracts: Thirty-Third Annual CTRC\u2010AACR San Antonio Breast Cancer Symposium\u2010\u2010 Dec 8\u201012, 2010; San Antonio, TX"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS10-P6-04-04", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T17:08:51Z", "timestamp": 1558199331000}, "score": 30.497, "issued": {"date-parts": [[2010, 12, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS10-P6-04-04"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-04-04"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T00:44:25Z", "timestamp": 1575247465130}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2018, 2, 15]]}, "DOI": "10.1158/1538-7445.sabcs17-p1-10-13", "type": "proceedings-article", "created": {"date-parts": [[2018, 2, 15]], "date-time": "2018-02-15T17:58:14Z", "timestamp": 1518717494000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P1-10-13: Olaparib nanoformulation in H-ferritin as a promising option for both BRCA-mutated and sporadic triple negative breast cancer: An in vitro study"], "prefix": "10.1158", "author": [{"given": "S", "family": "Mazzucchelli", "sequence": "first", "affiliation": []}, {"given": "M", "family": "Truffi", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Sorrentino", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Bellini", "sequence": "additional", "affiliation": []}, {"given": "MA", "family": "Rizzuto", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Ottria", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Ciuffreda", "sequence": "additional", "affiliation": []}, {"given": "D", "family": "Prosperi", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Corsi", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2018, 2, 14]]}, "event": {"name": "Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.SABCS17-P1-10-13", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 20]], "date-time": "2019-05-20T12:51:48Z", "timestamp": 1558356708000}, "score": 29.720713, "issued": {"date-parts": [[2018, 2, 14]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.SABCS17-P1-10-13"], "URL": "http://dx.doi.org/10.1158/1538-7445.sabcs17-p1-10-13"}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T01:26:14Z", "timestamp": 1574817974606}, "reference-count": 39, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://creativecommons.org/licenses/by/4.0", "start": {"date-parts": [[2017, 8, 8]], "date-time": "2017-08-08T00:00:00Z", "timestamp": 1502150400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Sci Rep"], "published-print": {"date-parts": [[2017, 12]]}, "DOI": "10.1038/s41598-017-07617-7", "type": "journal-article", "created": {"date-parts": [[2017, 8, 2]], "date-time": "2017-08-02T08:17:15Z", "timestamp": 1501661835000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 10, "title": ["H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer"], "prefix": "10.1038", "volume": "7", "author": [{"ORCID": "http://orcid.org/0000-0001-6904-8895", "authenticated-orcid": false, "given": "S.", "family": "Mazzucchelli", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Truffi", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Baccarini", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Beretta", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Sorrentino", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Bellini", "sequence": "additional", "affiliation": []}, {"given": "M. A.", "family": "Rizzuto", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Ottria", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Ravelli", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0003-2227-1373", "authenticated-orcid": false, "given": "P.", "family": "Ciuffreda", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Prosperi", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Corsi", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 8, 8]]}, "reference": [{"issue": "3", "key": "7617_CR1", "doi-asserted-by": "crossref", "first-page": "139", "DOI": "10.1038/nrclinonc.2009.234", "volume": "7", "author": "S Cosimo Di", "year": "2010", "unstructured": "Di Cosimo, S. & Baselga, J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat Rev Clin Oncol. 7(3), 139 (2010).", "journal-title": "Nat Rev Clin Oncol."}, {"issue": "15", "key": "7617_CR2", "doi-asserted-by": "crossref", "first-page": "12890", "DOI": "10.18632/oncotarget.3849", "volume": "6", "author": "DF Le", "year": "2015", "unstructured": "Le, D. F. et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 6(15), 12890 (2015).", "journal-title": "Oncotarget"}, {"key": "7617_CR3", "unstructured": "Chiorean, R., Braicu, C. & Berindan-Neagoe, I. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast 22(6), 1026 (2013).", "DOI": "10.1016/j.breast.2013.08.007", "doi-asserted-by": "crossref"}, {"key": "7617_CR4", "unstructured": "Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L. A. & King, T. A. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol 22(3), 874 (2015).", "DOI": "10.1245/s10434-014-4279-0", "doi-asserted-by": "crossref"}, {"issue": "1", "key": "7617_CR5", "doi-asserted-by": "crossref", "first-page": "27", "DOI": "10.1038/nrclinonc.2014.163", "volume": "12", "author": "A Sonnenblick", "year": "2015", "unstructured": "Sonnenblick, A., de Azambuja, E., Azim, H. A. Jr. & Piccart, M. An update on PARP inhibitors\u2013moving to the adjuvant setting. Nat Rev Clin Oncol. 12(1), 27 (2015).", "journal-title": "Nat Rev Clin Oncol."}, {"issue": "4", "key": "7617_CR6", "doi-asserted-by": "crossref", "first-page": "427", "DOI": "10.1517/14728222.2014.882900", "volume": "18", "author": "JF Carvalho", "year": "2014", "unstructured": "Carvalho, J. F. & Kanaar, R. Targeting homologous recombination-mediated DNA repair in cancer. Expert Opin Ther Targets. 18(4), 427 (2014).", "journal-title": "Expert Opin Ther Targets."}, {"key": "7617_CR7", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.1016/j.ejca.2016.03.005", "volume": "60", "author": "JA Ledermann", "year": "2016", "unstructured": "Ledermann, J. A., Drew, Y. & Kristeleit, R. S. Homologous recombination deficiency and ovarian cancer. Eur J Cancer 60, 49 (2016).", "journal-title": "Eur J Cancer"}, {"key": "7617_CR8", "doi-asserted-by": "crossref", "first-page": "455", "DOI": "10.1146/annurev-med-050913-022545", "volume": "66", "author": "CJ Lord", "year": "2015", "unstructured": "Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 66, 455 (2015).", "journal-title": "Annu Rev Med."}, {"key": "7617_CR9", "doi-asserted-by": "crossref", "first-page": "814", "DOI": "10.1038/nrc1457", "volume": "4", "author": "N Turner", "year": "2004", "unstructured": "Turner, N., Tutt, A. & Ashworth, A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4, 814 (2004).", "journal-title": "Nat Rev Cancer"}, {"key": "7617_CR10", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1016/S0140-6736(10)60892-6", "volume": "376", "author": "A Tutt", "year": "2010", "unstructured": "Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235 (2010).", "journal-title": "Lancet"}, {"key": "7617_CR11", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa0900212", "volume": "361", "author": "PC Fong", "year": "2009", "unstructured": "Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med. 361, 123 (2009).", "journal-title": "N Engl J Med."}, {"key": "7617_CR12", "doi-asserted-by": "crossref", "first-page": "852", "DOI": "10.1016/S1470-2045(11)70214-5", "volume": "12", "author": "KA Gelmon", "year": "2011", "unstructured": "Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12, 852 (2011).", "journal-title": "Lancet Oncol"}, {"key": "7617_CR13", "first-page": "401", "volume": "11", "author": "J Mateo", "year": "2016", "unstructured": "Mateo, J. et al. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. Targ. Oncol 11, 401 (2016).", "journal-title": "Oncol"}, {"key": "7617_CR14", "doi-asserted-by": "crossref", "first-page": "949", "DOI": "10.1007/s10637-012-9922-7", "volume": "31", "author": "N Bundred", "year": "2013", "unstructured": "Bundred, N. et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 31, 949 (2013).", "journal-title": "Invest New Drugs"}, {"key": "7617_CR15", "doi-asserted-by": "crossref", "first-page": "12670", "DOI": "10.1038/srep12670", "volume": "5", "author": "R Dufour", "year": "2015", "unstructured": "Dufour, R. et al. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep. 5, 12670 (2015).", "journal-title": "Sci Rep."}, {"key": "7617_CR16", "doi-asserted-by": "crossref", "first-page": "496", "DOI": "10.1021/mp800049w", "volume": "5", "author": "SD Li", "year": "2008", "unstructured": "Li, S. D. & Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5, 496 (2008).", "journal-title": "Mol Pharm"}, {"key": "7617_CR17", "doi-asserted-by": "crossref", "first-page": "1706", "DOI": "10.1002/smll.200801602", "volume": "5", "author": "A Maham", "year": "2009", "unstructured": "Maham, A., Tang, Z., Wu, H., Wang, J. & Lin, Y. Protein-based nanomedicine platforms for drug delivery. Small 5, 1706 (2009).", "journal-title": "Small"}, {"issue": "3", "key": "7617_CR18", "doi-asserted-by": "crossref", "first-page": "149", "DOI": "10.4155/tde.15.95", "volume": "7", "author": "F Corsi", "year": "2016", "unstructured": "Corsi, F. & Mazzucchelli, S. The potential of protein-based nanocages for imaging and drug delivery. Ther. Deliv. 7(3), 149 (2016).", "journal-title": "Ther. Deliv."}, {"key": "7617_CR19", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1016/j.phrs.2016.03.002", "volume": "107", "author": "M Truffi", "year": "2016", "unstructured": "Truffi, M. et al. Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol. Res. 107, 57 (2016).", "journal-title": "Pharmacol. Res."}, {"issue": "2", "key": "7617_CR20", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1158/0008-5472.CAN-13-1224", "volume": "74", "author": "W Wang", "year": "2014", "unstructured": "Wang, W. et al. IRP2 regulates breast tumor growth. Cancer Res. 74(2), 497 (2014).", "journal-title": "Cancer Res."}, {"key": "7617_CR21", "doi-asserted-by": "crossref", "first-page": "1305", "DOI": "10.1002/adhm.201500226", "volume": "4", "author": "L Zhang", "year": "2015", "unstructured": "Zhang, L. et al. A natural nuclei targeting and bioactive delivery nanovector. Adv. Healthcare Mater. 4, 1305 (2015).", "journal-title": "Adv. Healthcare Mater."}, {"key": "7617_CR22", "doi-asserted-by": "crossref", "first-page": "184", "DOI": "10.1016/j.jconrel.2014.10.002", "volume": "196", "author": "M Bellini", "year": "2014", "unstructured": "Bellini, M. et al. Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in cancer cells. J. ControlledRel. 196, 184 (2014).", "journal-title": "J. ControlledRel."}, {"key": "7617_CR23", "first-page": "8383", "volume": "8", "author": "S Mazzucchelli", "year": "2016", "unstructured": "Mazzucchelli, S. et al. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity. Oncotarget. 8, 8383 (2016).", "journal-title": "Oncotarget."}, {"issue": "2", "key": "7617_CR24", "doi-asserted-by": "crossref", "first-page": "170", "DOI": "10.1038/ncb1352", "volume": "8", "author": "K Muthumani", "year": "2006", "unstructured": "Muthumani, K. et al. The HIV-1 Vpr and glucorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol. 8(2), 170 (2006).", "journal-title": "Nat Cell Biol."}, {"issue": "6", "key": "7617_CR25", "doi-asserted-by": "crossref", "first-page": "4830", "DOI": "10.1021/nn305791q", "volume": "7", "author": "Z Zhen", "year": "2013", "unstructured": "Zhen, Z. et al. RGD-modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors. ACS Nano 7(6), 4830 (2013).", "journal-title": "ACS Nano"}, {"key": "7617_CR26", "doi-asserted-by": "crossref", "first-page": "649", "DOI": "10.1007/s10549-012-2106-5", "volume": "134", "author": "H-C Chuang", "year": "2012", "unstructured": "Chuang, H.-C. et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple negative breast cancer cells. Breast Cancer Res. Treat. 134, 649\u2013659 (2012).", "journal-title": "Breast Cancer Res. Treat."}, {"issue": "3", "key": "7617_CR27", "doi-asserted-by": "crossref", "first-page": "270", "DOI": "10.1200/JOP.2016.010710", "volume": "12", "author": "S Hong", "year": "2016", "unstructured": "Hong, S. et al. Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and \u201cBRCAness\u201d Mutations. J Oncol Pract. 12(3), 270 (2016).", "journal-title": "J Oncol Pract."}, {"issue": "1", "key": "7617_CR28", "doi-asserted-by": "crossref", "first-page": "293", "DOI": "10.1186/s13063-016-1423-0", "volume": "17", "author": "PC Schouten", "year": "2016", "unstructured": "Schouten, P. C. et al. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials. 17(1), 293 (2016).", "journal-title": "Trials."}, {"issue": "4", "key": "7617_CR29", "doi-asserted-by": "crossref", "first-page": "557", "DOI": "10.2217/fon.14.268", "volume": "11", "author": "W Jacot", "year": "2015", "unstructured": "Jacot, W., Theillet, C., Guiu, S. & Lamy, P. J. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations? Future Oncol. 11(4), 557 (2015).", "journal-title": "Future Oncol."}, {"issue": "7", "key": "7617_CR30", "doi-asserted-by": "crossref", "first-page": "e0159341", "DOI": "10.1371/journal.pone.0159341", "volume": "11", "author": "S Ito", "year": "2016", "unstructured": "Ito, S., Murphy, C. G., Doubrovina, E., Jasin, M. & Moynahan, M. E. PARP inhibitors in clinical use induce genomic instability in normal human cells. PLoS One 11(7), e0159341 (2016).", "journal-title": "PLoS One"}, {"key": "7617_CR31", "doi-asserted-by": "crossref", "first-page": "3505", "DOI": "10.1073/pnas.0913192107", "volume": "107", "author": "L Li", "year": "2010", "unstructured": "Li, L. et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. USA 107, 3505 (2010).", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"issue": "3", "key": "7617_CR32", "doi-asserted-by": "crossref", "first-page": "291", "DOI": "10.1016/j.bbagen.2011.07.016", "volume": "1820", "author": "TR Daniels", "year": "2012", "unstructured": "Daniels, T. R. et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 1820(3), 291 (2012).", "journal-title": "Biochim Biophys Acta."}, {"issue": "1B", "key": "7617_CR33", "first-page": "541", "volume": "21", "author": "DC Yang", "year": "2001", "unstructured": "Yang, D. C., Wang, F., Elliott, R. L. & Head, J. F. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res. 21(1B), 541 (2001).", "journal-title": "Anticancer Res."}, {"key": "7617_CR34", "first-page": "2165", "volume": "115", "author": "KJ Thompson", "year": "2002", "unstructured": "Thompson, K. J., Fried, M. G., Ye, Z., Boyer, P. & Connor, J. R. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. Cell Sci. 115, 2165 (2002).", "journal-title": "Cell Sci."}, {"key": "7617_CR35", "doi-asserted-by": "crossref", "first-page": "731", "DOI": "10.1042/BJ20041853", "volume": "388", "author": "N Surguladze", "year": "2005", "unstructured": "Surguladze, N., Patton, S., Cozzi, A., Fried, M. G. & Connor, J. R. Characterization of nuclear ferritin and mechanism of translocation. Biochem. J. 388, 731 (2005).", "journal-title": "Biochem. J."}, {"issue": "36", "key": "7617_CR36", "doi-asserted-by": "crossref", "first-page": "14381", "DOI": "10.1073/pnas.1212366109", "volume": "109", "author": "N Singh", "year": "2012", "unstructured": "Singh, N. et al. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proc Natl Acad Sci USA. 109(36), 14381 (2012).", "journal-title": "Proc Natl Acad Sci USA."}, {"issue": "3", "key": "7617_CR37", "doi-asserted-by": "crossref", "first-page": "291", "DOI": "10.1007/s10577-010-9178-z", "volume": "19", "author": "CL Rieder", "year": "2011", "unstructured": "Rieder, C. L. Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints. Chromosome Res. 19(3), 291 (2011).", "journal-title": "Chromosome Res."}, {"issue": "6", "key": "7617_CR38", "doi-asserted-by": "crossref", "first-page": "2805", "DOI": "10.1039/C4NR07102F", "volume": "7", "author": "JM Caster", "year": "2015", "unstructured": "Caster, J. M. et al. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale. 7(6), 2805 (2015).", "journal-title": "Nanoscale."}, {"key": "7617_CR39", "doi-asserted-by": "crossref", "first-page": "2189", "DOI": "10.2217/fon-2016-0116", "volume": "19", "author": "G Roviello", "year": "2016", "unstructured": "Roviello, G. et al. A Phase II study of olaparibin breast cancer patients: biological evaluation from a \u2018window of opportunity\u2019 trial. Future Oncol. 19, 2189 (2016).", "journal-title": "Future Oncol."}], "container-title": ["Scientific Reports"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/s41598-017-07617-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/s41598-017-07617-7", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/s41598-017-07617-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 2]], "date-time": "2017-08-02T08:17:28Z", "timestamp": 1501661848000}, "score": 29.396107, "issued": {"date-parts": [[2017, 8, 8]]}, "references-count": 39, "journal-issue": {"published-print": {"date-parts": [[2017, 12]]}, "issue": "1"}, "alternative-id": ["7617"], "URL": "http://dx.doi.org/10.1038/s41598-017-07617-7", "relation": {"cites": []}, "ISSN": ["2045-2322"], "issn-type": [{"value": "2045-2322", "type": "electronic"}], "article-number": "7505"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:58:45Z", "timestamp": 1574539125976}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 12, 15]]}, "DOI": "10.1158/0008-5472.sabcs13-p2-12-02", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:26:43Z", "timestamp": 1408055203000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract P2-12-02: Characteristics of the BRCA mutation profile of a population of patients with triple negative breast cancer"], "prefix": "10.1158", "author": [{"given": "E", "family": "Luporsi", "sequence": "first", "affiliation": []}, {"given": "M", "family": "Bronner", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Lesur", "sequence": "additional", "affiliation": []}, {"given": "D", "family": "Saint-Dizier", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Sokolowska", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Mansuy", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Jonveaux", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 3, 26]]}, "event": {"name": "Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS13-P2-12-02", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T19:53:14Z", "timestamp": 1558209194000}, "score": 29.063866, "issued": {"date-parts": [[2013, 12, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS13-P2-12-02"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs13-p2-12-02"}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T03:25:52Z", "timestamp": 1576639552756}, "reference-count": 47, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 9, 14]], "date-time": "2012-09-14T00:00:00Z", "timestamp": 1347580800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res Treat"], "published-print": {"date-parts": [[2012, 11]]}, "DOI": "10.1007/s10549-012-2232-0", "type": "journal-article", "created": {"date-parts": [[2012, 9, 13]], "date-time": "2012-09-13T05:56:46Z", "timestamp": 1347515806000}, "page": "67-75", "source": "Crossref", "is-referenced-by-count": 29, "title": ["Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer"], "prefix": "10.1007", "volume": "136", "author": [{"given": "Veronique M.", "family": "Neumeister", "sequence": "first", "affiliation": []}, {"given": "Catherine A.", "family": "Sullivan", "sequence": "additional", "affiliation": []}, {"given": "Robert", "family": "Lindner", "sequence": "additional", "affiliation": []}, {"given": "Kimberley", "family": "Lezon-Geyda", "sequence": "additional", "affiliation": []}, {"given": "Jia", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "Jan", "family": "Zavada", "sequence": "additional", "affiliation": []}, {"given": "Maritza", "family": "Martel", "sequence": "additional", "affiliation": []}, {"given": "Peter M.", "family": "Glazer", "sequence": "additional", "affiliation": []}, {"given": "David P.", "family": "Tuck", "sequence": "additional", "affiliation": []}, {"given": "David L.", "family": "Rimm", "sequence": "additional", "affiliation": []}, {"given": "Lyndsay", "family": "Harris", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 9, 14]]}, "reference": [{"issue": "6871", "key": "2232_CR1", "doi-asserted-by": "crossref", "first-page": "530", "DOI": "10.1038/415530a", "volume": "415", "author": "LJ Veer van\u2019t", "year": "2002", "unstructured": "van\u2019t Veer LJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530\u2013536", "journal-title": "Nature"}, {"issue": "5", "key": "2232_CR2", "doi-asserted-by": "crossref", "first-page": "295", "DOI": "10.1053/ctrv.2001.0233", "volume": "27", "author": "MO Nicoletto", "year": "2001", "unstructured": "Nicoletto MO et al (2001) BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev 27(5):295\u2013304", "journal-title": "Cancer Treat Rev"}, {"issue": "2", "key": "2232_CR3", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1016/S0092-8674(02)00615-3", "volume": "108", "author": "AR Venkitaraman", "year": "2002", "unstructured": "Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171\u2013182", "journal-title": "Cell"}, {"issue": "3", "key": "2232_CR4", "doi-asserted-by": "crossref", "first-page": "362", "DOI": "10.1016/S0959-8049(97)89007-7", "volume": "33", "author": "OT Johannsson", "year": "1997", "unstructured": "Johannsson OT et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33(3):362\u2013371", "journal-title": "Eur J Cancer"}, {"issue": "19", "key": "2232_CR5", "doi-asserted-by": "crossref", "first-page": "1482", "DOI": "10.1093/jnci/djg050", "volume": "95", "author": "WD Foulkes", "year": "2003", "unstructured": "Foulkes WD et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482\u20131485", "journal-title": "J Natl Cancer Inst"}, {"issue": "1", "key": "2232_CR6", "doi-asserted-by": "crossref", "first-page": "64", "DOI": "10.1158/0008-5472.CAN-03-2570", "volume": "64", "author": "ZC Wang", "year": "2004", "unstructured": "Wang ZC et al (2004) Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64(1):64\u201371", "journal-title": "Cancer Res"}, {"issue": "7", "key": "2232_CR7", "doi-asserted-by": "crossref", "first-page": "1145", "DOI": "10.1200/JCO.2009.22.4725", "volume": "28", "author": "DP Silver", "year": "2010", "unstructured": "Silver DP et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145\u20131153", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "2232_CR8", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1016/j.critrevonc.2004.07.002", "volume": "52", "author": "A Feki", "year": "2004", "unstructured": "Feki A, Irminger-Finger I (2004) Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52(2):103\u2013116", "journal-title": "Crit Rev Oncol Hematol"}, {"issue": "22", "key": "2232_CR9", "doi-asserted-by": "crossref", "first-page": "3165", "DOI": "10.1038/sj.onc.1210975", "volume": "27", "author": "L Melchor", "year": "2008", "unstructured": "Melchor L et al (2008) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27(22):3165\u20133175", "journal-title": "Oncogene"}, {"issue": "6", "key": "2232_CR10", "doi-asserted-by": "crossref", "first-page": "490", "DOI": "10.1002/gcc.20550", "volume": "47", "author": "W Han", "year": "2008", "unstructured": "Han W et al (2008) DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosom Cancer 47(6):490\u2013499", "journal-title": "Genes Chromosom Cancer"}, {"issue": "17", "key": "2232_CR11", "doi-asserted-by": "crossref", "first-page": "2501", "DOI": "10.1038/sj.onc.1210885", "volume": "27", "author": "J Tommiska", "year": "2008", "unstructured": "Tommiska J et al (2008) The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27(17):2501\u20132506", "journal-title": "Oncogene"}, {"issue": "24", "key": "2232_CR12", "doi-asserted-by": "crossref", "first-page": "8010", "DOI": "10.1158/1078-0432.CCR-08-1208", "volume": "14", "author": "BP Schneider", "year": "2008", "unstructured": "Schneider BP et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010\u20138018", "journal-title": "Clin Cancer Res"}, {"issue": "24", "key": "2232_CR13", "doi-asserted-by": "crossref", "first-page": "11597", "DOI": "10.1158/0008-5472.CAN-05-2119", "volume": "65", "author": "RS Bindra", "year": "2005", "unstructured": "Bindra RS et al (2005) Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65(24):11597\u201311604", "journal-title": "Cancer Res"}, {"issue": "1", "key": "2232_CR14", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1038/nrc704", "volume": "2", "author": "AL Harris", "year": "2002", "unstructured": "Harris AL (2002) Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38\u201347", "journal-title": "Nat Rev Cancer"}, {"issue": "4", "key": "2232_CR15", "doi-asserted-by": "crossref", "first-page": "678", "DOI": "10.1038/cdd.2008.21", "volume": "15", "author": "EB Rankin", "year": "2008", "unstructured": "Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15(4):678\u2013685", "journal-title": "Cell Death Differ"}, {"issue": "10", "key": "2232_CR16", "doi-asserted-by": "crossref", "first-page": "721", "DOI": "10.1038/nrc1187", "volume": "3", "author": "GL Semenza", "year": "2003", "unstructured": "Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721\u2013732", "journal-title": "Nat Rev Cancer"}, {"issue": "1", "key": "2232_CR17", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1002/ijc.10904", "volume": "104", "author": "RE Airley", "year": "2003", "unstructured": "Airley RE et al (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104(1):85\u201391", "journal-title": "Int J Cancer"}, {"issue": "4", "key": "2232_CR18", "doi-asserted-by": "crossref", "first-page": "1177", "DOI": "10.1016/j.ijrobp.2008.12.004", "volume": "73", "author": "J Russell", "year": "2009", "unstructured": "Russell J et al (2009) Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys 73(4):1177\u20131186", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"issue": "4", "key": "2232_CR19", "first-page": "995", "volume": "24", "author": "M Rafajova", "year": "2004", "unstructured": "Rafajova M et al (2004) Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 24(4):995\u20131004", "journal-title": "Int J Oncol"}, {"issue": "21", "key": "2232_CR20", "doi-asserted-by": "crossref", "first-page": "6421", "DOI": "10.1158/1078-0432.CCR-06-0480", "volume": "12", "author": "DJ Brennan", "year": "2006", "unstructured": "Brennan DJ et al (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12(21):6421\u20136431", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "2232_CR21", "first-page": "73", "volume": "41", "author": "BA Teicher", "year": "1981", "unstructured": "Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41(1):73\u201381", "journal-title": "Cancer Res"}, {"issue": "7", "key": "2232_CR22", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1038/nrm1963", "volume": "7", "author": "V Schreiber", "year": "2006", "unstructured": "Schreiber V et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7(7):517\u2013528", "journal-title": "Nat Rev Mol Cell Biol"}, {"issue": "2", "key": "2232_CR23", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa0900212", "volume": "361", "author": "PC Fong", "year": "2009", "unstructured": "Fong PC et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123\u2013134", "journal-title": "N Engl J Med"}, {"issue": "3", "key": "2232_CR24", "doi-asserted-by": "crossref", "first-page": "861", "DOI": "10.1007/s10549-011-1441-2", "volume": "127", "author": "P Domagala", "year": "2011", "unstructured": "Domagala P et al (2011) PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 127(3):861\u2013869", "journal-title": "Breast Cancer Res Treat"}, {"issue": "6\u20137", "key": "2232_CR25", "doi-asserted-by": "crossref", "first-page": "315", "DOI": "10.1002/emmm.200900041", "volume": "1", "author": "AM Mendes-Pereira", "year": "2009", "unstructured": "Mendes-Pereira AM et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6\u20137):315\u2013322", "journal-title": "EMBO Mol Med"}, {"issue": "10", "key": "2232_CR26", "doi-asserted-by": "crossref", "first-page": "814", "DOI": "10.1038/nrc1457", "volume": "4", "author": "N Turner", "year": "2004", "unstructured": "Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4(10):814\u2013819", "journal-title": "Nat Rev Cancer"}, {"issue": "8", "key": "2232_CR27", "doi-asserted-by": "crossref", "first-page": "812", "DOI": "10.1177/1947601910383418", "volume": "1", "author": "V Ossovskaya", "year": "2010", "unstructured": "Ossovskaya V et al (2010) Upregulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1(8):812\u2013821", "journal-title": "Genes Cancer"}, {"key": "2232_CR28", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1186/1756-8722-4-16", "volume": "4", "author": "Y Yuan", "year": "2011", "unstructured": "Yuan Y et al (2011) Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4:16", "journal-title": "J Hematol Oncol"}, {"issue": "1 Pt 1", "key": "2232_CR29", "doi-asserted-by": "crossref", "first-page": "173", "DOI": "10.1158/1078-0432.CCR-0699-3", "volume": "10", "author": "HM Kluger", "year": "2004", "unstructured": "Kluger HM et al (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173\u2013177", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "2232_CR30", "doi-asserted-by": "crossref", "first-page": "1323", "DOI": "10.1038/nm791", "volume": "8", "author": "RL Camp", "year": "2002", "unstructured": "Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11):1323\u20131327", "journal-title": "Nat Med"}, {"issue": "6", "key": "2232_CR31", "doi-asserted-by": "crossref", "first-page": "1067", "DOI": "10.1038/sj.bjc.6601264", "volume": "89", "author": "J Zavada", "year": "2003", "unstructured": "Zavada J et al (2003) Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89(6):1067\u20131071", "journal-title": "Br J Cancer"}, {"issue": "6", "key": "2232_CR32", "doi-asserted-by": "crossref", "first-page": "857", "DOI": "10.1016/j.humpath.2007.10.011", "volume": "39", "author": "EA Rakha", "year": "2008", "unstructured": "Rakha EA et al (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39(6):857\u2013865", "journal-title": "Hum Pathol"}, {"issue": "2", "key": "2232_CR33", "doi-asserted-by": "crossref", "first-page": "236", "DOI": "10.1038/6029", "volume": "21", "author": "CA Wilson", "year": "1999", "unstructured": "Wilson CA et al (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21(2):236\u2013240", "journal-title": "Nat Genet"}, {"issue": "5", "key": "2232_CR34", "doi-asserted-by": "crossref", "first-page": "621", "DOI": "10.1369/jhc.4A6544.2005", "volume": "53", "author": "F Al-Mulla", "year": "2005", "unstructured": "Al-Mulla F et al (2005) BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem 53(5):621\u2013629", "journal-title": "J Histochem Cytochem"}, {"key": "2232_CR35", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1186/1471-2407-8-17", "volume": "8", "author": "JZ Press", "year": "2008", "unstructured": "Press JZ et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17", "journal-title": "BMC Cancer"}, {"issue": "6", "key": "2232_CR36", "doi-asserted-by": "crossref", "first-page": "875", "DOI": "10.1177/548.6505", "volume": "96", "author": "F Rastelli", "year": "2010", "unstructured": "Rastelli F et al (2010) Triple-negative breast cancer: current state of the art. Tumori 96(6):875\u2013888", "journal-title": "Tumori"}, {"issue": "14", "key": "2232_CR37", "doi-asserted-by": "crossref", "first-page": "2126", "DOI": "10.1038/sj.onc.1210014", "volume": "26", "author": "NC Turner", "year": "2007", "unstructured": "Turner NC et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126\u20132132", "journal-title": "Oncogene"}, {"issue": "4", "key": "2232_CR38", "doi-asserted-by": "crossref", "first-page": "444", "DOI": "10.1038/ng0495-444", "volume": "9", "author": "ME Thompson", "year": "1995", "unstructured": "Thompson ME et al (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9(4):444\u2013450", "journal-title": "Nat Genet"}, {"issue": "16", "key": "2232_CR39", "first-page": "3347", "volume": "57", "author": "A Dobrovic", "year": "1997", "unstructured": "Dobrovic A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57(16):3347\u20133350", "journal-title": "Cancer Res"}, {"issue": "2", "key": "2232_CR40", "doi-asserted-by": "crossref", "first-page": "179", "DOI": "10.1007/s10549-004-7603-8", "volume": "91", "author": "E Matros", "year": "2005", "unstructured": "Matros E et al (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91(2):179\u2013186", "journal-title": "Breast Cancer Res Treat"}, {"issue": "3", "key": "2232_CR41", "doi-asserted-by": "crossref", "first-page": "921", "DOI": "10.1677/erc.1.01216", "volume": "13", "author": "D Generali", "year": "2006", "unstructured": "Generali D et al (2006) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 13(3):921\u2013930", "journal-title": "Endocr Relat Cancer"}, {"issue": "10", "key": "2232_CR42", "first-page": "1279", "volume": "26", "author": "C Pinheiro", "year": "2011", "unstructured": "Pinheiro C et al (2011) GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 26(10):1279\u20131286", "journal-title": "Histol Histopathol"}, {"issue": "3", "key": "2232_CR43", "doi-asserted-by": "crossref", "first-page": "593", "DOI": "10.1007/s12253-010-9355-6", "volume": "17", "author": "L Beketic-Oreskovic", "year": "2011", "unstructured": "Beketic-Oreskovic L et al (2011) Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2\u2032-deoxyguanosine (8-OHdG) in breast cancer patients. Pathol Oncol Res 17(3):593\u2013603", "journal-title": "Pathol Oncol Res"}, {"issue": "1", "key": "2232_CR44", "doi-asserted-by": "crossref", "first-page": "104", "DOI": "10.1038/sj.bjc.6603530", "volume": "96", "author": "SA Hussain", "year": "2007", "unstructured": "Hussain SA et al (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96(1):104\u2013109", "journal-title": "Br J Cancer"}, {"issue": "1", "key": "2232_CR45", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1016/j.currproblcancer.2010.12.002", "volume": "35", "author": "MK Weil", "year": "2011", "unstructured": "Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35(1):7\u201350", "journal-title": "Curr Probl Cancer"}, {"issue": "4", "key": "2232_CR46", "doi-asserted-by": "crossref", "first-page": "334", "DOI": "10.1093/jnci/djq509", "volume": "103", "author": "Y Drew", "year": "2011", "unstructured": "Drew Y et al (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103(4):334\u2013346", "journal-title": "J Natl Cancer Inst"}, {"issue": "3", "key": "2232_CR47", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1056/NEJMoa1011418", "volume": "364", "author": "J O\u2019Shaughnessy", "year": "2011", "unstructured": "O\u2019Shaughnessy J et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214", "journal-title": "N Engl J Med"}], "container-title": ["Breast Cancer Research and Treatment"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s10549-012-2232-0.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s10549-012-2232-0/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s10549-012-2232-0", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 3]], "date-time": "2019-07-03T20:45:23Z", "timestamp": 1562186723000}, "score": 28.766212, "issued": {"date-parts": [[2012, 9, 14]]}, "references-count": 47, "journal-issue": {"published-print": {"date-parts": [[2012, 11]]}, "issue": "1"}, "alternative-id": ["2232"], "URL": "http://dx.doi.org/10.1007/s10549-012-2232-0", "relation": {"cites": []}, "ISSN": ["0167-6806", "1573-7217"], "issn-type": [{"value": "0167-6806", "type": "print"}, {"value": "1573-7217", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T00:14:56Z", "timestamp": 1575245696223}, "reference-count": 0, "publisher": "Alphamed Press", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Oncologist"], "published-print": {"date-parts": [[2013, 7, 1]]}, "DOI": "10.1634/theoncologist.2013-0380", "type": "journal-article", "created": {"date-parts": [[2013, 7, 3]], "date-time": "2013-07-03T04:44:11Z", "timestamp": 1372826651000}, "page": "802-811", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Triple-Negative Breast Cancers: Associations Between Imaging and Pathological Findings for Triple-Negative Tumors Compared With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers"], "prefix": "10.1634", "volume": "18", "author": [{"given": "M.", "family": "Boisserie-Lacroix", "sequence": "first", "affiliation": []}, {"given": "G.", "family": "MacGrogan", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Debled", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Ferron", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Asad-Syed", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "McKelvie-Sebileau", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Mathoulin-Pelissier", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Brouste", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Hurtevent-Labrot", "sequence": "additional", "affiliation": []}], "member": "638", "published-online": {"date-parts": [[2013, 7, 2]]}, "container-title": ["The Oncologist"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1634/theoncologist.2013-0380", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T00:06:40Z", "timestamp": 1482451600000}, "score": 28.610163, "issued": {"date-parts": [[2013, 7, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 7, 23]]}, "published-print": {"date-parts": [[2013, 7, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1634/theoncologist.2013-0380", "ISSN": ["1083-7159", "1549-490X"], "issn-type": [{"value": "1083-7159", "type": "print"}, {"value": "1549-490X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T20:42:43Z", "timestamp": 1574368963181}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 4, 1]], "date-time": "2008-04-01T00:00:00Z", "timestamp": 1207008000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2008, 4]]}, "DOI": "10.1016/s1359-6349(08)70422-1", "type": "journal-article", "created": {"date-parts": [[2008, 5, 10]], "date-time": "2008-05-10T09:49:11Z", "timestamp": 1210412951000}, "page": "79-80", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Basal- and non-basal phenotypes in triple-negative breast cancers"], "prefix": "10.1016", "volume": "6", "author": [{"given": "P.", "family": "Sinn", "sequence": "first", "affiliation": []}, {"given": "Z.", "family": "Sawaf", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Schirmacher", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634908704221?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634908704221?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 28]], "date-time": "2018-12-28T21:57:18Z", "timestamp": 1546034238000}, "score": 28.521559, "issued": {"date-parts": [[2008, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 4]]}, "issue": "7"}, "alternative-id": ["S1359634908704221"], "URL": "http://dx.doi.org/10.1016/s1359-6349(08)70422-1", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T18:31:08Z", "timestamp": 1574361068598}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2008, 4, 1]]}, "DOI": "10.1158/1078-0432.ccr-07-4100", "type": "journal-article", "created": {"date-parts": [[2008, 4, 1]], "date-time": "2008-04-01T18:40:22Z", "timestamp": 1207075222000}, "page": "1976-1983", "source": "Crossref", "is-referenced-by-count": 16, "title": ["Familial Breast Cancers without Mutations in BRCA1 or BRCA2 Have Low Cyclin E and High Cyclin D1 in Contrast to Cancers in BRCA Mutation Carriers"], "prefix": "10.1158", "volume": "14", "author": [{"given": "K.", "family": "Aaltonen", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Blomqvist", "sequence": "additional", "affiliation": []}, {"given": "R.-M.", "family": "Amini", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Eerola", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Aittomaki", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Heikkila", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Nevanlinna", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-07-4100", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T03:40:10Z", "timestamp": 1482464410000}, "score": 28.299202, "issued": {"date-parts": [[2008, 4, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 4, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-07-4100", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T05:33:50Z", "timestamp": 1575264830818}, "reference-count": 0, "publisher": "Alphamed Press", "issue": "9", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Oncologist"], "published-print": {"date-parts": [[2013, 9, 1]]}, "DOI": "10.1634/theoncologist.2013-0121", "type": "journal-article", "created": {"date-parts": [[2013, 8, 20]], "date-time": "2013-08-20T02:13:12Z", "timestamp": 1376964792000}, "page": "1060-1061", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers"], "prefix": "10.1634", "volume": "18", "author": [{"given": "F.", "family": "Bertucci", "sequence": "first", "affiliation": []}, {"given": "P.", "family": "Finetti", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Viens", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Birnbaum", "sequence": "additional", "affiliation": []}], "member": "638", "published-online": {"date-parts": [[2013, 8, 19]]}, "container-title": ["The Oncologist"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1634/theoncologist.2013-0121", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T00:13:37Z", "timestamp": 1482452017000}, "score": 28.103914, "issued": {"date-parts": [[2013, 8, 19]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 9, 23]]}, "published-print": {"date-parts": [[2013, 9, 1]]}, "issue": "9"}, "URL": "http://dx.doi.org/10.1634/theoncologist.2013-0121", "ISSN": ["1083-7159", "1549-490X"], "issn-type": [{"value": "1083-7159", "type": "print"}, {"value": "1549-490X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T03:24:54Z", "timestamp": 1575429894078}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "11_Supplement", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Prevention Research"], "published-print": {"date-parts": [[2012, 11, 1]]}, "DOI": "10.1158/1940-6207.prev-12-b104", "type": "journal-article", "created": {"date-parts": [[2014, 1, 23]], "date-time": "2014-01-23T19:55:39Z", "timestamp": 1390506939000}, "page": "B104-B104", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract B104: Expressions of PCNA in triple negative breast cancers and Their clinical significance"], "prefix": "10.1158", "volume": "5", "author": [{"given": "P.", "family": "Jiaping", "sequence": "first", "affiliation": []}, {"given": "m.", "family": "qun", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 1, 23]]}, "container-title": ["Cancer Prevention Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1940-6207.PREV-12-B104", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T11:14:28Z", "timestamp": 1482491668000}, "score": 28.057796, "issued": {"date-parts": [[2012, 11, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 1, 23]]}, "published-print": {"date-parts": [[2012, 11, 1]]}, "issue": "11_Supplement"}, "URL": "http://dx.doi.org/10.1158/1940-6207.prev-12-b104", "ISSN": ["1940-6207", "1940-6215"], "issn-type": [{"value": "1940-6207", "type": "print"}, {"value": "1940-6215", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T16:35:10Z", "timestamp": 1574094910377}, "reference-count": 19, "publisher": "Elsevier BV", "issue": "11", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1998, 10, 1]], "date-time": "1998-10-01T00:00:00Z", "timestamp": 907200000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[1998, 10]]}, "DOI": "10.1016/s0959-8049(98)00248-2", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T12:15:57Z", "timestamp": 1027599357000}, "page": "1683-1686", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers"], "prefix": "10.1016", "volume": "34", "author": [{"given": "P", "family": "Osin", "sequence": "first", "affiliation": []}, {"given": "B.A", "family": "Gusterson", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Philp", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Waller", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Bartek", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Peto", "sequence": "additional", "affiliation": []}, {"given": "T", "family": "Crook", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804998002482?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804998002482?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 30]], "date-time": "2019-04-30T21:24:19Z", "timestamp": 1556659459000}, "score": 27.729979, "issued": {"date-parts": [[1998, 10]]}, "references-count": 19, "journal-issue": {"published-print": {"date-parts": [[1998, 10]]}, "issue": "11"}, "alternative-id": ["S0959804998002482"], "URL": "http://dx.doi.org/10.1016/s0959-8049(98)00248-2", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}